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“Twenty years from now you will be more disappointed by the things that you didn’t do 
than by the ones you did do. So throw off the bowlines. Sail away from the safe harbor. 
Catch the trade winds in your sails. Explore. Dream. Discover.”   
Mark Twain  
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Thesis Abstract 
Cancer remains a leading cause of morbidity and mortality despite better understanding of 
cancer causation and progression. Current anticancer regimens are associated with non-
specific cytotoxicity leading to treatment failure due to serious toxic effects to normal tissue 
and the development of treatment resistant disease. Gene therapy offers the potential for 
selective targeting of tumour cells with little or no effects on normal tissue. However, gene 
therapy clinical trials have failed to replicate preclinical success. This may be due to the use 
of models that do not accurately resemble the complexity of in vivo conditions or mimic the 
heterogeneity of tumour tissues. As a consequence, we hypothesise that the use of patient 
tumour tissue would provide a promising preclinical model for the study of gene delivery 
methods prior to clinical application.  
Chapter 1 begins with an introduction to cancer and the current challenges facing its 
management. The review discusses various gene delivery vectors and looks at ways of 
enhancing gene delivery by incorporating a strategy of organ selective gene delivery based on 
vector and organ characteristics. The review aims to identify the most appropriate gene 
delivery method and route of administration, taking into consideration characteristic 
anatomical features and physiological barriers of the affected organ together with clinical 
hallmarks of the disease.  
In Chapter 2 we discuss the development of an ex vivo patient tissue model for the study of 
various gene delivery methods. We found that patient tumour samples could be maintained 
viable in culture conditions for ex vivo cultivation and appropriately respond to gene delivery 
treatments. We developed a novel tumour slice model culture system that is universally 
applicable to gene delivery methods, using a real-time luminescence detection method to 
assess gene delivery. This study demonstrated that Ad-mediated delivery and gene expression 
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was generally superior to other methods examined while US proved the optimal non-
biological gene delivery method in patient tumour slices. The nature of the ex vivo culture 
system permitted examination of specific physiological variables and the influence of 
intratumoural factors. Parameters shown to diminish Ad gene delivery included blood, 
regions of low viability and secondary disease. The ex vivo model was also suitable for 
examination of tissue specific effects on vector expression. Ad under the control of the 
human CXCR4 promoter demonstrated a 'tumour on' and 'normal off' expression profile when 
compared with the ubiquitously active CMV promoter when tested in patient breast tumour 
tissue. For the investigation of vector efficacy, toxicity and target cell specificity we 
optimised a dissociation technique, which provides representative cells from the entire slice 
for the accurate assessment of viability and identification of targeted cell types. Tumour 
population analysis demonstrated that Ad mediated by CXCR targeted a higher percentage of 
tumour cells when compared with CMV. 
Chapter 3 looks at the potential for colorectal tumour targeting using transcriptional targeting 
strategies.  An ex vivo cultured patient colorectal tumour model was employed to examine Ad 
transduction of colorectal tumours. Ad under the control of the human CXCR4 promoter 
demonstrated low reporter gene expression in normal colon and liver tissue while providing 
high expression in colorectal tumours when compared with the CMV promoter. In addition, 
we investigate the effects of hypoxia on adenoviral gene delivery. Hypoxia is an important 
feature of solid tumours as a consequence of a structurally and functionally disturbed 
microcirculation and directly facilitates the development of treatment resistance. We 
developed an ex vivo system of changing oxygenation using the hypoxia inducer, cobalt, to 
mimic the transient hypoxic conditions found in solid tumours. We found that  Ad-related 
transgene expression varied depending on the level of hypoxia, with significantly reduced 
levels observed with prolonged hypoxia. However, transgene expression was robust in the 
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cycling hypoxic conditions relevant to solid tumours and re-oxygenation of chronically 
hypoxic tissue enhanced transgene expression. 
In Chapter 4, we developed an AAV-based tumour targeting vector using the tumour-
selective promoter CXCR4.  The AAVCXCR4 vector demonstrated efficient tumour-
selective expression when locally administered to subcutaneous tumours and normal tissue. 
Population analysis showed that AAVCXCR4 preferentially targets epithelial tumour and 
CXCR4-expressing cells while the CMV promoter demonstrated majority expression in non-
tumour and non-CXCR4-positive cell types. Comparison of the expression kinetics of CMV 
with CXCR4 following systemic delivery in hepatic tumour murine models revealed that 
AAV mediated by the CXCR4 promoter retained high expression in tumours-bearing livers 
while maintaining low expression in tumour free livers. Furthermore, AAVCXCR4 retained 
the tumour-selective nature in ex vivo patient breast tumour tissues, confirming the 
translational potential of this vector. 
This is the first study incorporating patient tissue models in comparing gene delivery from 
various vectors, providing knowledge on cell-type specificity and examining the crucial 
biological factors determining successful gene delivery. We also demonstrate the potential of 
tumour specific promoters using viral vectors to enhance tumour selectivity over normal 
tissue. The results highlight the importance of in-depth preclinical assessment of novel 
therapeutics and may serve as a platform for further testing of current, novel gene delivery 
approaches. 
 
  8 
Publications  
1. Adenovirus-mediated transcriptional targeting of colorectal cancer and effects 
on treatment-resistant hypoxic cells. Simon Rajendran, Gerald C O’Sullivan, 
Deirdre O’ Hanlon, and Mark Tangney. Clinical Colorectal Cancer, 2013 
Sep;12(3):152-162. PMID: 23313233. 
2. Targeting of breast metastases using viral gene vector with tumour selective 
transcription. Simon Rajendran, Sara Collins, Jan P van Pijkeren, Deirdre O’ 
Hanlon, Gerald C O’Sullivan and Mark Tangney. Anticancer Research 2011 
May;31(5):1627-35. PMID: 21617219 
3. Preclinical evaluation of gene delivery methods for the treatment of loco-regional 
disease in breast cancer. Simon Rajendran, Deirdre O’Hanlon, David Morrissey, 
Tracey O’Donovan, Gerald C. O’Sullivan, Mark Tangney. Experimental Biology and 
Medicine 2011 Apr 1;236(4):423-34. PMID 21444371 
4. Control and augmentation of long-term plasmid transgene expression in vivo in 
murine muscle tissue and ex vivo in patient mesenchymal tissue. David Morrissey, 
Jan P van Pijkeren JP, Simon Rajendran, Sara A Collins, Gareth Casey, Gerald C 
O'Sullivan, Mark Tangney. Journal of Biomedicine and Biotechnology. 
2012;2012:37984. PMID: 22811595 
5. A Listeria monocytogenes-based DNA delivery system for cancer gene therapy. . 
Jan Peter Van Pijkeren, David Morrissey, Michelle Cronin, Simon Rajendran, Gerald 
C. O’Sullivan, Cormac  G.M. Gahan, Mark Tangney. Human Gene Therapy. 2010 
Apr;21(4):405-16. PMID: 20105075 
 
  9 
6. Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. 
Alexandra Buhles,
 
Sara A Collins, Jan P van Pijkeren, Simon Rajendran, Michelle 
Miles, Gerald C O'Sullivan, Deirdre M O'Hanlon and Mark Tangney. Genetic 
Vaccines and Therapy, 2009 Mar 9;7:5. PMID: 19272140                                          
7. Orally administered bifidobacteria as vehicles for delivery of agents to systemic 
tumours. Michelle Cronin, David Morrissey, Simon Rajendran, SM El Mashad, D 
van Sinderen, Gerald C O'Sullivan, Mark Tangney. Molecular Therapy, 2010 
Jul;18(7):1397-407. PMID: 20389288                                                                                                                  
Video Articles 
1. Ex vivo culture of patient tissue and examination of gene delivery. Simon 
Rajendran, Slawomir Salwa, Xuefeng Gao, Sabin Tabirca, Deirdre O'Hanlon, 
Gerald C. O'Sullivan and Mark Tangney. Journal of Visualized Experiments, 2010 
Dec 20;(46). PMID: 21326169 
2. Murine bioluminescent hepatic tumour model. Simon Rajendran, Slawomir 
Salwa, Xuefeng Gao, Sabin Tabirca, Deirdre O'Hanlon, Gerald C. O'Sullivan and 
Mark Tangney. Journal of Visualized Experiments. 2010 Jul 17;(41). PMID: 
20689502 
Book Chapters 
1. Book title: Gene Therapy - developments and future perspectives (ISBN 978-953-
307-617-1) Chapter title: Comparison of DNA Delivery and Expression Using 
Frequently Used Delivery Methods. Sara Collins, David Morrissey, Simon 
Rajendran, Garrett Casey, Martina Scallan, Patrick Harrison, Gerald O’Sullivan and 
Mark Tangney 
  10 
Oral Presentations 
 
1. Adenovirus-mediated transcriptional targeting of colorectal cancer and effects 
on treatment resistant hypoxic cells. Simon Rajendran, Gerald C O’Sullivan, 
Deirdre O’ Hanlon, and Mark Tangney. Society of Academic and Research Surgery 
Meeting, Nottingham 2012 
 
2. Targeting of breast metastases using a viral gene vector with tumour-selective 
transcription. Simon Rajendran, Sara Collins, Jan P van Pijkeren, Deirdre O’ 
Hanlon, Gerald C O’Sullivan and Mark Tangney. Plenary session, Sir Peter Freyer 
Memorial Lecture, Galway 2011  
 
3. A novel ex vivo model for the study of gene delivery to patient tissue. Simon 
Rajendran, Deirdre O’Hanlon, David Morrissey, Tracey O’Donovan, Gerald C. 
O’Sullivan, Mark Tangney. Irish Association for Cancer Research, Athlone 2009 
 
  
  11 
Declaration  
 
I hereby declare that I am the sole author of this thesis.  
I authorise University College Cork to lend and photocopy this thesis to other institutions or 
individuals for the purpose of scholarly research. 
 
 
 
 
 
 
----------------------------------------------------------- 
 
Simon Rajendran 
 
                                                                    
 
  
  12 
Acknowledgements 
 
First and foremost I wish to express my sincerest gratitude to my supervisors, Dr. Mark 
Tangney for his patient and knowledgeable support throughout my research and to Ms. 
Deirdre O'Hanlon, without whose motivation and encouragement I would not have embarked 
on this journey.  A special mention goes to the late Professor Gerry O'Sullivan, whose 
infectious enthusiasm and immense knowledge was truly inspirational. I would also like to 
thank everyone at CCRC, South Infirmary Victoria Hospital and Pathology Department, 
Mercy Hospital for their support, friendship and generosity in sharing their time and 
expertise. Finally, I would also like to thank my family, especially my parents for their 
constant prayers and guidance throughout my life and my wife, Marie Claire, without whose 
love, encouragement and editing assistance, I would not have finished this thesis. 
 
 
 
 
 
 
 
 
 
 
  13 
Abbreviations 
 
AAV    Adeno-associated virus 
Ad    Adenovirus 
ATCC    American Type Culture Collection 
BBB    Blood Brain Barrier 
BLI    Bioluminescent Imaging 
CAR    Coxsackievirus -adenovirus receptor 
CCRC    Cork Cancer Research Centre 
CMV    Cytomegalovirus  
cm    Centimetre    
CNS    Central Nervous System 
CRC    Colorectal Cancer 
CSF    Cerebrospinal Fluid 
CXCR4   CXC - Chemokine Receptor 4 
Cy5    Cyanine 5 
DMEM    Dulbecco Modified Eagle Medium 
DNA    Deoxyribonucleic Acid 
EGF    Epidermal Growth Factor  
EP    Electroporation 
FBS    Foetal Bovine Serum 
FUS    Focussed Ultrasound 
h    Hour 
HCC    Hepatocellular Carcinoma 
HIV    Human Immunodeficiency Virus 
HSPG    Heparin Sulphate Proteoglycans 
HSV    Herpes Simplex Virus  
IV    Intravenous 
IVIS    In vivo Imaging System 
kb    kilo Bases 
Lipo    Lipofection 
LPS    Lipopolysaccharide 
MEM    Minimum Essential Medium 
min    Minutes 
ml    Millilitres 
mm    Millimetres 
  14 
mRNA    Messenger RNA 
msec    Millisecond 
NaCl    Sodium Chloride 
O2    Oxygen 
PBS    Phosphate Buffered Saline  
PE    Phycoerythrin 
PEI    Polyethyleneimine 
PI    Propidium Iodide 
RNA    Ribonucleic Acid 
ROI    Region of Interest 
RT    Room Temperature 
X-SCID   X-linked Severe Combined Immunodeficiency Disease  
SRE    Skeletal-Related Events 
ssDNA    Single-Stranded DNA  
ssRNA    Single-Stranded RNA 
TLR9    Toll-like Receptor 9 
TSP    Tumour Specific Promoter 
U    Units 
US    Ultrasound 
VATS    Video-assisted Thoracoscopy  
VEGFR   Vascular Endothelium Growth Factor 
µg    micrograms 
µl    microlitres 
µsec     microseconds 
 C    Degrees Celsius 
 
 
  
  15 
Chapter 1 
Literature Review 
The Road Ahead -  Breast Cancer Gene Therapy  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  16 
Table of contents 
Abstract __________________________________________________________________ 17 
1.1 Introduction ___________________________________________________________ 18 
1.2 Gene Delivery Methods __________________________________________________ 22 
1.2.1 Identification of suitable strategy ____________________________________________ 22 
1.2.2 Biological methods ________________________________________________________ 24 
1.2.2.1 Viral vectors __________________________________________________________________ 24 
1.2.2.1.1 Retrovirus ________________________________________________________________ 25 
1.2.2.1.2 Lentivirus ________________________________________________________________ 26 
1.2.2.1.3 Herpes Simplex Virus _______________________________________________________ 26 
1.2.2.1.4 Adeno-Associated virus _____________________________________________________ 27 
1.2.2.1.5 Adenovirus _______________________________________________________________ 29 
1.2.2.2 Bacterial vectors _______________________________________________________________ 30 
1.2.2.2.1 Salmonella _______________________________________________________________ 33 
1.2.2.2.2 Listeria monocytogenes _____________________________________________________ 33 
1.2.2.2.3 Bifidobacteria _____________________________________________________________ 34 
1.2.3 Non-biological methods ____________________________________________________ 35 
1.2.3.1 Plasmid based gene delivery _____________________________________________________ 35 
1.2.3.1.1 Chemical methods _________________________________________________________ 36 
1.2.3.1.1.1 Calcium phosphate ____________________________________________________ 36 
1.2.3.1.1.2 Cationic lipids ________________________________________________________ 37 
1.2.3.1.1.2 Cationic polymers _____________________________________________________ 38 
1.2.3.1.2 Physical methods __________________________________________________________ 39 
1.2.3.1.2.1 Direct needle injection _________________________________________________ 39 
1.2.3.1.2.2 Hydrodynamics _______________________________________________________ 40 
1.2.3.1.2.3 Particle bombardment _________________________________________________ 41 
1.2.3.1.2.4 Electroporation _______________________________________________________ 41 
1.2.3.1.2.5 Ultrasound ___________________________________________________________ 42 
1.3 Clinical relevance _______________________________________________________ 43 
1.3.1 Which method when? _____________________________________________________ 43 
1.3.2 Breast Cancer ____________________________________________________________ 44 
1.3.2.1 Localised Disease ______________________________________________________________ 44 
1.3.2.2 Metastatic Disease _____________________________________________________________ 48 
1.3.2.2.1 Liver ____________________________________________________________________ 49 
1.3.2.2.2 Brain ____________________________________________________________________ 52 
1.3.2.2.3 Bone ____________________________________________________________________ 55 
1.3.2.2.4 Lung ____________________________________________________________________ 56 
1.4 Discussion_____________________________________________________________ 58 
1.4.1 Limitations ______________________________________________________________ 60 
1.5 Conclusions ___________________________________________________________ 61 
 
  
  17 
Abstract 
The major challenge of anti-cancer therapy is lack of specificity leading to treatment resistant disease. 
The ideal therapeutic would selectively eradicate tumour cells with minimum effects on normal tissue. 
Gene therapies have emerged as realistic prospects for the treatment of cancer due to their potential 
for selective tumour cell targeting.  The most significant hurdle for clinical application however, 
depends on the ability to efficiently deliver sufficient therapeutic genes to the target site. This 
chapter reviews the suitability of various gene delivery methods as potential vehicles of 
therapeutic genes detailing the mechanisms of action and major obstacles along with recent 
advances in vector development to overcome or circumvent these difficulties. The merits of 
different gene delivery methods are discussed to assess the current feasibility of each in 
specific stages of  cancer progression. The review discusses ways of enhancing gene delivery 
by incorporating a strategy of organ selective gene delivery based on vector and organ 
characteristics. The review aims to identify the most appropriate gene delivery method and 
route of administration, taking into consideration characteristic anatomical features and 
physiological barriers of the affected organ together with clinical hallmarks of the disease. 
We end with a brief perspective of the ethical concerns and commercial viability of cancer 
gene therapy.  
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1.1 Introduction  
Cancer is the uncontrolled growth of cells in the presence of environmental stimuli leading to 
tissue invasion which may be localised or distant.  Cancer can present at any age and afflicts 
all tissue types, including epithelial, mesenchymal, haematopoietic or embryonic tissue, 
making it the leading cause of mortality in all ages. Malignant cancer cells have the ability to 
invade, migrate and survive in distant organs and therefore the initial diagnosis is made at 
various stages in their progression, from being localised to widespread disease. In the last 
decade significant strides have been made in improving cancer treatment due to the better 
understanding of cellular, genetic and molecular mechanisms, which provide targets for 
treatments to prevent, detect, eradicate or control disease (1). The identification of cancers at 
earlier clinical stages has been shown to improve treatment outcome and long term prognosis. 
Successful treatment outcomes are often achieved after complete surgical resection of disease 
that is localised within a single organ. Remarkably, a surgical cure was already hypothesised 
in the 18th century by the "Father of Scientific Surgery" Scottish surgeon John Hunter (2) 
(Figure 1.1). However the lack of knowledge in the area of anaesthesia at the time prevented 
implementation.  The success achieved from treating early localised disease encouraged 
widespread cancer awareness initiatives and the development of universal screening 
programs targeting numerous cancer types, including breast, prostate, cervical and colorectal. 
Changes in cancer risk behaviour, new detection and screening strategies and the 
development and implementation of new and more effective treatments have decreased 
cancer related mortality in certain cancer types (1). Despite these efforts, patients continue to 
present with disease at late stages leading to poor treatment outcomes and cancer related 
mortality remain high for certain cancers. The main reasons hypothesised for this are the 
indolent nature of certain cancers, the unpredictable nature of cancer progression and despite 
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widespread cancer awareness initiatives, late presentation of patients in spite of symptom 
development.                                     
Major advances made in the understanding of the genetic basis of cancer is driving the 
development of alternative treatment strategies. Gene therapy is a relatively new member of 
the anti-cancer armamentarium which currently include traditional strategies of surgery, 
chemotherapy and radiation and more recent additions involving hormonal manipulation and 
biological agents. Gene therapy is the transfer of exogenous genes, called transgenes into 
cells which can be accomplished by a number of methods (3). The product of the transgene 
serves to either cure or restrict advancement of disease. The concept of gene therapy initially 
arose in the 1960s, and began to gain prominence in the early 1970s; where strategies initially 
focused on the replacement of loss of function as a treatment for monogenetic disorders, 
including cystic fibrosis and muscle dystrophy (4). While the first successful gene therapy 
case was conducted in 1990 in a 4-year old child with adenosine deaminase severe combined 
immunodeficiency (ADA-SCID) (5, 6), the first complete gene therapy cure however, was 
only achieved ten years later in children with X-linked severe combined immunodeficiency 
disease (X-SCID). The optimism generated by the first true success using gene therapy was 
subsequently challenged by significant failures. Two of the ten children cured from X-SCID 
developed T-cell leukaemia, which was the direct result of the gene delivery vector, 
Retrovirus (RV); integrating near the LMO2 proto-oncogene promoter, a phenomenon known 
as insertional mutagenesis, leading to aberrant transcription and expression of LMO2 which 
plays a crucial in haematopoietic development (7, 8). Furthermore, the first gene therapy 
death, Jesse Gelsinger in September 1999, occurred as a result of a severe immune response 
to the gene delivery vector, Adenovirus (Ad) raising concerns regarding the safety of gene 
therapy treatments. Despite these setbacks, gene therapy offers enormous therapeutic  
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potential and as of June 2012 more than 1840 gene therapy clinical trials are being conducted 
in 31 countries worldwide using a number of gene therapy techniques (8). In addition to the 
treatment of genetic disease, gene therapy has been shown to have significant potential as a 
cancer therapeutic. Conventional non-invasive cancer treatment frequently causes serious 
side effects due to their non-specific effects, which eventually limits their potential 
therapeutic dose (9). Owing to this narrow therapeutic window, complete eradication of 
localised advanced or metastatic disease is rarely achieved, resulting in residual disease 
becoming refractory to treatment (9). Furthermore, approximately 30 % of all patients with 
early-stage breast cancer develop recurrent disease which is metastatic in most cases (10). In 
this respect, the application of gene therapy to cancer has attracted great attention because of 
its potential capability for selective targeting and killing of cancer cells with reduced normal 
tissue toxicities. Furthermore, gene therapy can theoretically be used in the adjuvant, 
neoadjuvant and metastatic settings and therefore may offer an alternative treatment option in 
patients with local and widespread metastatic disease. Currently, nearly 65 % of all gene 
therapy trials have been aimed at the treatment of cancer (8). Over the past decade, many 
gene therapy strategies have been devised.  As has been the case with previous gene therapy 
trials, despite the effectiveness of any therapeutic strategy, the potential success of treatment 
is largely dependent on the application of a suitable gene delivery method. With this 
background in mind we have reviewed various gene delivery methods and their suitability for 
cancer gene therapy. Because of the huge amount of novel gene delivery methods we have 
primarily focused on important clinical aspects of gene delivery for breast cancer and the 
advantages it may offer as a new treatment option in this subset of patients.  
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1.2 Gene Delivery Methods 
1.2.1 Identification of suitable strategy 
The main objective in cancer gene therapy is efficient and effective delivery of therapeutic 
genes to cancer cells with little or no effects on normal cells.  Therefore, a major hurdle for 
clinical application of gene therapy in cancer is the development of a gene delivery strategy 
that is both efficient and non-toxic and commercially viable. However, the specific 
requirements of the delivery system will also vary according to the type of cancer and clinical 
stage of disease. Various gene delivery methods have been developed and each has its own 
merits as a suitable vector in breast cancer gene therapy. The most commonly used gene 
delivery methods for cancer treatment and their physical attributes that make them the ideal 
cancer gene delivery agent in a particular setting are the focus of this review. 
In order to achieve a therapeutic effect any gene delivery method should be able to deliver 
genes of interest to the designated target and to ensure their expression for an appropriate 
amount of time. Gene expression is regulated by a complex interplay of factors that function 
in a cell-type-specific manner to produce diverse effects. Numerous gene delivery methods 
have been developed during the past two decades and can be broadly divided into two distinct 
groups; non-biological and biological. (Figure 1.2). Biological methods involves the use of 
viruses which can be either RNA or DNA viruses and bacterial vectors. Non-biological 
methods involve the use of chemical or physical approaches to transfer genetic material 
carried on plasmid DNA. Although non-viral approaches are being used increasingly, viral 
vectors remain by far the most common  approach, having been used in approximately two-
thirds of clinical trials performed to date (8). This part of the review will include a brief 
discussion on commonly used gene delivery methods in gene therapy clinical trials (8), 
highlighting the properties that make them suitable for cancer gene therapy. We will then 
discuss the current challenges in the management of breast cancer and the potential role gene 
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therapy may play in this setting. We focus on the suitability of various gene delivery 
methods, examining both potential advantages and limitations depending on the stage and site 
of disease   
  
1.2.2 Biological methods 
For more than two decades there was been widespread scientific interest in the utilisation of  
biological agents for the delivery of cytotoxic or therapeutic genes to cancer cells. This 
strategy aims to exploit the natural ability of disease causing microorganisms to evade the 
body's natural surveillance system and invade tumour or tumour associated cells. The first 
virus used for gene therapy was from the family of murine RV. Since then a wide variety of 
both DNA and RNA viruses have been studied for gene delivery. More recently bacterial 
vectors have shown promise as a tumour specific gene delivery vehicle.  
 
1.2.2.1 Viral vectors  
Viruses are natural DNA carriers that can very efficiently introduce foreign DNA into host 
cells. This innate ability was first harnessed in the 1970s and since then viruses have become 
the most widely used gene carrier in clinical trials. The most commonly used viral vectors in 
cancer gene therapy are derived from Ad, Adeno-associated virus (AAV), Lentivirus (LV), 
RV and Herpes Simplex Virus (HSV). The vast majority of cancer gene therapy has been 
carried out using replication-defective viral vectors with replication-defective Ad being the 
most commonly used vector (8). Viral vectors may be categorised into integrating and non-
integrating, with AAV, RV and LV able to integrate their viral genome into the chromosomal 
DNA of the host, while both Ad and HSV deliver viral genomes to the nucleus of the host 
and remain episomal.  
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1.2.2.1.1 Retrovirus 
RV belong to a family of enveloped RNA viruses, the Retroviridae, found in all vertebrates 
and can be classed into oncoretroviruses, LV and spumaviruses. RV consists of a double 
stranded RNA encapsulated by a protein core surrounded by a lipid bilayer (11). This lipid 
envelope contains polypeptide chains including receptor binding proteins. These receptor 
binding proteins link to membrane receptors of the host cell. Following attachment of the RV 
envelope to the target cell receptors, a fusion event between the viral lipid membrane and 
cellular membrane allows viral entry into target cells.  Therefore, RV receptors and entry co-
factors determine the tropism of this vector. RV also contain the enzymes reverse 
transcriptase (RTase) and integrase which mediate reverse transcription into viral DNA using 
the virus RNA as a template. During transduction, the virus injects viral RNA into the 
cytoplasm of the target cell along with the reverse transcriptase enzyme. The DNA produced 
from the RNA template contains the virally derived genetic instructions and allows 
transduction of the target cell to proceed. Viral DNA enters the nucleus and viral DNA is 
integrated into the target cell genome. The most important advantage that RV offer is high 
efficiency gene delivery to target cells that allow for long term and stable expression. This is 
due to their ability to transform their single stranded RNA into double stranded DNA that 
stably integrates into the target cell genome (12). A major limitation in their use is the 
inability to infect non-dividing cells. RV require nuclear envelope breakdown  in mitosis to 
allow the viral genome to access the target cell genome and undergo integration (13). 
Furthermore, non-specific integration leading to deleterious effects such as insertional 
mutagenesis as was seen in the X-SCID clinical trial illustrated the potential dangers involved 
as a consequence of using RV.  These factors have resulted in a decline in the use of RV 
vectors (8).  
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1.2.2.1.2 Lentivirus  
LV, a subset of the Retroviridae are unique among RV because of their ability to infect target 
cells independently of their proliferation status (14). Much of the development of these 
vectors has focussed on human immunodeficiency virus (HIV). The advantage of using HIV 
based vectors is that these vectors can accommodate relatively large gene inserts and possess 
a pre-integration complex than allows viral genome to move through the nuclear membrane 
without requiring mitosis. Therefore, unlike retroviral vectors, this mechanistic feature allows 
LV to target both dividing and non-dividing cells whilst still demonstrating sustained stable 
gene expression through chromosomal integration. Commercial limitations include difficulty 
in producing high titre viral stocks. Regarding safety, questions still remain as to the potential 
risk of insertional mutagenesis and furthermore, scrutiny regarding the use of vectors derived 
from HIV remain due to the serious clinical consequences of the wild-type virus. This has 
resulted in the study of other LV, including HIV-2, primate LV such as Simian 
Immunodeficiency Virus  and non-primate LV such as Feline Immunodeficiency Virus  and 
Equine Infectious Anaemia Virus and these vectors are currently under preclinical 
development for gene therapy (15).  
 
1.2.2.1.3 Herpes Simplex Virus  
Herpesviridae encompass a large family of DNA viruses that include HSV-1 and 2, Varicella 
Zoster Virus, Epstein-Barr Virus and Cytomegalovirus (CMV). Herpesviridae are ubiquitous 
in the human population with more than 90 % of adults been infected with at least one of 
these viruses. Among the herpesviruses, neurotrophic herpesviruses such HSV-1 and HSV-2 
are unique among viruses currently under development as gene delivery vectors in that they 
have the ability to infect axonal nerve terminals before retrograde transport to neuronal cell 
bodies. In the neuronal cell bodies, latency, a state where viral genomes persist for the entire 
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life of the host as intranuclear episomal elements is established (16, 17). During latency HSV 
is not naturally cleared by the immune system and host cells remain undamaged. HSV has 
many favourable properties for clinical application. The main advantages of using HSV 
vectors include easy production of non-pathogenic vector, efficient gene delivery to a broad 
range of tissues due to the wide expression of cellular receptors recognised by the virus, the 
ability to accommodate large or multiple gene inserts due to the large viral genome and 
finally it has the capability of persisting in a lifelong non-integrated latent state without 
causing disease in the immune-competent host (18, 19), therefore demonstrating the potential 
for a long-term therapeutic benefit. The limitations associated with HSV vectors include an 
inability to retain expression of inserted genes during latency, as these genes like the majority 
of the HSV genome during latency, become rapidly transcriptionally inactivated. Long-term 
expression can be achieved by using elements from the latently active region of the virus to 
confer a long-term activity onto a number of promoters which otherwise function only in the 
short term and also allows multiple inserted genes to be expressed from HSV vectors during 
latency (18-20).   
 
1.2.2.1.4 Adeno-Associated virus   
AAV is a small non-enveloped, non-pathogenic human virus commonly found in the human 
respiratory or gastrointestinal tract. AAV has rapidly gained popularity in the field of gene 
since the establishment of the first infectious clone of AAV serotype 2 in 1982 (21).  AAV 
are members of the Parvovirus family, specifically the Dependovirus subfamily and require a 
helper virus, usually Ad or HSV in order to complete its life cycle (22). The AAV genome is 
a small (∼4.7 kb), linear single-stranded DNA molecule. AAV are capable of both latent and 
lytic infections. They can remain dormant in an integrated state, or replicate in the cell, 
induce lysis with release of particles. Viral entry by AAV is mediated by binding to its 
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primary receptor heparin sulphate proteoglycans (HSPG) (23).  Reported co-receptors of 
AAV include αvβ5 integrin, fibroblast growth factor receptor 1 (FGFR-1) and hepatocyte 
growth factor (c-Met), although this has been disputed by some groups (24, 25). Following 
entry into the cell and transfer into the nuclear compartment, the single stranded AAV 
genomes are slowly converted to double-stranded molecules. The second strand synthesis is 
dependent on cellular DNA polymerases, and appears to be the rate-limiting step in AAV 
expression (26). In the presence of helper functions such as those provided by Ad, 
transcription generated from three distinct viral promoters, p5, p19 and p40 is upregulated, 
producing rep and cap proteins which play a role in viral replication. While in the absence of 
a helper virus, AAV can either integrate into the host genome at a specific site on 
chromosome 19, known as AAVS1 or persist as an episomal form (27-29). There are 
currently twelve different human serotypes of AAV described in the literature (30, 31) and 
more than a hundred serotypes from non-human primates have been discovered to date (32). 
AAV2 is the most widely used human serotype for gene delivery studies (32). The variation 
in capsid proteins between serotypes impart different binding characteristics, altering the 
biodistribution and transduction efficiency. This provides the ability to cross-package or 
pseudotype AAV vectors into capsids from other serotypes. Cross-packaging has shown to 
combine characteristics from two serotypes generating a vector with the desired target cell 
profile whilst maintaining a serotypes characteristic safety profile. AAV are considered 
favourable gene delivery vectors as they offer stable and persistent gene expression (33) to 
both dividing and non-dividing target cells. The widespread distribution of its primary 
receptor HSPG on many cell types explains the broad tropism of AAV vectors. AAV in 
general has an excellent safety profile which when combined with its many serotypes and 
reduced potential for activation of inflammatory or cellular immune responses has made this 
vector an attractive option for cancer treatment and clinical application (32).   
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1.2.2.1.5 Adenovirus 
Ad are non-enveloped icosahedral medium sized (90 - 100 nm) viruses with a 36 kb double 
stranded DNA genome. Since their isolation from human adenoid tissue by Rowe and 
colleagues in 1953 (34), Ad have become the most extensively studied gene delivery vectors 
(35, 36) being used in more than 24 % of gene therapy trials worldwide (8). Fifty-seven 
different serotypes of Ad have been identified so far, and these are divided into six subgroups 
A-F (37). The most commonly used serotypes are serotype 2 (Ad2) and 5 (Ad5) of subgroup 
C.  Host cell entry of Ad requires two distinct, sequential steps, binding and internalisation.  
All subgroups excluding subgroup B, attaches to the cell by binding to the primary cellular 
receptor Coxsackie-Adenovirus Receptor (CAR) (38, 39).  The globular knob domain of the 
Ad trimeric fibre capsid protein is responsible for binding to CAR and initiating 
internalisation.  Besides CAR, Ad may use other molecules as receptors for binding, 
including the major histocompatibility complex I (MHCI) and heparin sulfate 
glycosaminoglycans. Internalisation is mediated via integrin (αvβ3/5) mediated endocytosis 
following the interaction of the integrins with the viral penton base protein. The virion then 
escapes from the endosome and localises to the nuclear pore, whereupon its genome is 
translocated to the nucleus where the primary transcription events are initiated. The genome 
remains extra-chromosomal, which minimises the risk of insertional mutagenesis. Expression 
of the adenoviral genes is temporally regulated. E1A is the first transcription unit to be 
expressed.  The E1A proteins activate transcription from other adenoviral early regions. The 
expression of the early adenoviral genes sets the stage for replication of the viral DNA (37, 
40, 41). The expression of the late Ad genes commences with the onset of DNA replication. 
A non-replicating Ad has complete deletion of the E1A region, preventing expression of the 
E2 genes and thus blocking viral DNA replication and synthesis of late structural proteins 
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except in the context of E1A-expressiong packaging cells. E1-deleted or the so-called “first-
generation” replication-deficient Ad vectors are the most widely used in gene delivery. 
The main advantages of Ad vectors are in their ability to deliver large therapeutic genes at 
high transduction efficiency in both dividing and non-dividing cells. The virus is relatively 
easy to produce in high titres for clinical use, possesses a broad tropism allowing targeting of 
a wide range of cells and comparable safety as the viral genome is not integrated into the host 
genome (41). Safety concerns about the use of Ad were raised following the death of Jesse 
Gelsinger from multi organ failure as a result of a severe immune response to the Ad vector 
used in the trial. The viral capsid proteins trigger an acute inflammatory response leading to 
the rapid release of inflammatory cytokines and recruitment of immune effector cells. The 
acute-phase toxicity depends on the dose of vector and does not require viral gene expression. 
Ad gene expression is only transient as the viral genome is not integrated into the host cell 
genome and furthermore, in many cases, the expressed transgene product has also been 
shown to be immunogenic. As a consequence of elimination of transduced cells by the 
acquired cellular immune response, transgene expression can be short lived. In addition, a 
humoural immune response is generated towards the Ad vector, leading to reduced 
effectiveness in repeat vector administration. Moreover, exposure to wild-type Ad is common 
in humans, therefore the presence of neutralising antibodies present in patients previously 
exposed to viruses will result in an immune response against the vector.  
 
1.2.2.2 Bacterial vectors                                                                              
The association of bacterial infections and tumour colonisation with regression is by no 
means a recent discovery.  At the beginning of the 19
th
 century, Vaultier observed that 
cancers regressed in patients with bacterial infections (42, 43).  In 1867, the German 
physician, W Busch reported the regression of an inoperable sarcoma in a patient with 
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Erysipelas infection, which was later identified to be Streptococcus pyogenes. William Coley, 
American bone surgeon and pioneer of cancer immunotherapy also characterised concomitant 
bacterial infections of tumours and attributed the regression of tumours to the induction of an 
immune response to bacterial products. This concept led to the creation of Coley's Toxins, a 
mixture of killed bacterial infusions, that were administered by injection directly into the 
tumour mass (Figure 1.1) (44). Despite achieving considerable treatment success, the 
unpredictable nature and serious effects of Coley's Toxins, coupled with the development of 
radiation and chemotherapy led to the gradual disappearance of bacterial therapy in anti-
cancer strategies until more recent times. The discovery of bacteria that specifically infiltrate 
and replicate preferentially within tumours and the advent of genomic sequencing and genetic 
engineering, began a renewed interest in the use of bacteria as gene delivery vectors.  
Bacteria, like viruses are natural DNA carriers that permit the efficient delivery of genes to 
target cells. Bacterial gene delivery is achieved by two broad approaches. The first approach 
known as bactofection is achieved by the direct entry of the entire bacterium into the cell (45-
47). Bactofection applies to both active invasion of non-phagocytic cells and to the passive 
uptake by phagocytic immune cells. For this review, we focus primarily on the use of active 
invasion of cells for gene delivery. The ability to actively invade a cell is typically found in 
pathogens. Different bacterial strains use different methods of cell invasion and following 
invasion they can be localised either primarily in the cytoplasm, vacuoles or in extracellular 
space. Once inside the cell, spontaneous or induced bacterial lysis leads to the release of 
plasmid DNA for subsequent gene expression. This trait was discovered less than 20 years 
ago and since then, various bacterial strains have demonstrated this ability. However, prior to 
clinical application, their pathological potential to invade normal cells must be eliminated 
(48-52) whilst retaining bactofection efficacy.  
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The second approach entails bacterial replication outside the target cells (47). Certain bacteria 
have shown the propensity to accumulate in tumours. Several theories have been postulated 
as to why bacteria replicate and survive, in some cases, specifically within tumours.  
Traditionally, the main mechanism believed to be responsible for tumour colonisation by 
bacteria was the hypoxic nature of solid tumours providing an ideal growth environment for 
anaerobic and facultative anaerobic bacteria. Recent theories propose that the leaky tumour 
vasculature allows bacteria to enter and lodge into tumours, necrotic areas within tumours 
serve as a source of nutrients in the form of purines for certain bacteria and that tumours 
provide immunological sanctuaries for bacteria where clearance mechanisms are inhibited 
allowing bacterial accumulation (53). Furthermore, the presence of chemoattrant compounds 
within necrotic zones may promote bacterial chemotaxis. This unique tumour homing 
characteristic allows the use of non-invasive strains to achieve tumour localised expression 
which occurs locally outside the tumour cells.  
Both these gene delivery approaches have their advantages however, to achieve success using 
either strategy, bacterial strains must ideally be non-pathogenic, non-immunogenic, have the 
ability to preferentially accumulate or replicate around or within the tumour cells and be 
susceptible to antibiotic for plasmid release and bacterial clearance. In addition significant 
effort must be made to prevent lateral gene transfer to other bacteria and to limit 
environmental spread of the vector (54). A safety property unique to bacterial vectors is the 
potential sensitivity to antibiotics, enabling vector control post-administration. We review 
two of the most commonly investigated bactofection vectors, Salmonella and Listeria along 
with Bifidobacteria which has been shown to have a strong predisposition to tumour 
colonisation following intravenous and oral administration (55).  
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1.2.2.2.1 Salmonella  
Salmonella are motile Gram-negative facultative anaerobes known to cause gastrointestinal 
infections in humans. Salmonella strains are known to colonise various types of cancers. 
Being a facultative anaerobe, they can colonise all areas of tumours independent of oxygen 
levels. Salmonella is currently the most widely used vector for bactofection. For bactofection, 
entry into the cytosol is the crucial step in plasmid transfer.  Following cell entry, Salmonella 
remain trapped in the target cell phagosome. The main advantages of bactofection are the 
simplicity of application, economical, and ability to transfer large DNA constructs.  The 
major drawbacks to using Salmonella in cancer gene therapy is that it is highly immunogenic 
which might result in rapid clearance of bacteria and /or induce tumour necrosis factor alpha 
(TNF-α) mediated septic shock.  
  
1.2.2.2.2 Listeria monocytogenes 
Listeria monocytogenes (L. monocytogenes) is a facultative, intracellular Gram-positive 
bacterium named after the imminent British surgeon Joseph Lister. L. monocytogenes is 
efficient in mediating internalization into host cells. Once inside the host cell, the bacterium 
produces specific virulence factors which lyse the vacuolar membrane and allow escape into 
the cytoplasm (56). Once in the cytosol, L. monocytogenes is capable of actin-based motility 
through the production of bacterial actin assembly-inducing protein which results in actin 
polymerisation. The continuous actin polymerization promotes motility in the cytoplasm and 
subsequent cell-to-cell spread (57). Cell-to-cell spread is achieved through the formation of 
protrusions into neighbouring cells, thus down-stream spread is achieved without an 
extracellular phase. When compared with other bactofection vectors, L. monocytogenes offers 
a number of advantages. L. monocytogenes is a gram positive organism, and therefore does 
not possess lipopolysaccharide (LPS) in the outer membrane like gram negative organisms 
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which act as endotoxins and elicit strong immune responses resulting in more rapid 
elimination of vector. The cytoplasmic location of L. monocytogenes unlike with other 
bacterial vectors such as E.coli and Salmonella which remain trapped in the host cell 
phagosome (58) is beneficial for the delivery of DNA. L. monocytogenes permits along with 
DNA the delivery of RNA or protein. It demonstrates amplification, local spread throughout 
the tumour and long-tem expression, which can be induced or silenced by antibiotic 
administration. Furthermore, unlike viral vectors, where vector synthesis is generally 
extremely cumbersome, time consuming and expensive, bacterial vectors are an economical 
and technically easier vector to manufacture (58). For successful bactofection, as with 
Salmonella, strains must have to be non-pathogenic, non-immunogenic, have the ability to 
preferentially accumulate and replicate within the tumours and be susceptible to antibiotic for 
plasmid release and bacterial clearance.  
 
1.2.2.2.3 Bifidobacteria 
Bifidobacteria is a non-motile, Gram positive, facultative anaerobic bacterium, first isolated 
in 1900 by Henry Tissier from a breast-fed infants. They are native, commensals of the 
human gastrointestinal system, and certain strains have been used as probiotics (53). 
Bifidobacteria have recently been shown to be effective delivery vehicles in the specific 
targeting of solid tumours when delivered by both intravenous and oral route. After 
application, its growth is limited to hypoxic areas such as the tissue of solid tumours. This 
feature potentially offers targeting of both primary and systemic disease (53, 55). The 
advantages of Bifidobacteria are its safety, easy to manufacture and its inert ability to home 
to and selectively replicate in tumours (55).  
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1.2.3 Non-biological methods 
Non-biological gene delivery generally refers to the transfer of plasmid DNA into cells by 
using chemical or physical methods. Chemical methods promote gene delivery by means of 
nano-carriers while physical methods either depend on the local delivery of a large volume of 
plasmid DNA, high pressure or the utilisation of various energy forms to generate transient 
pores on the cell membrane to facilitate gene delivery.  
 
1.2.3.1 Plasmid based gene delivery  
The term "plasmid" was introduced by Joshua Lederberg in 1952 to describe any 
extrachromosomal genetic particle (59, 60). Since about 1970, plasmids have become 
important reagents in molecular genetic research and biotechnology. For successful plasmid 
based gene delivery and subsequent expression in mammalian cells, plasmid DNA needs to 
overcome three major hurdles. The plasmid needs to travel from the site of administration to 
the surface of target cells. DNA are sensitive to the nucleases in biological matrices. Once at 
the surface the DNA needs to cross the plasma membrane into the cytoplasm.  Cell 
membranes are like sheets of amphipathic molecules that separate cells from their 
environment and form the boundaries of organelles within cells. DNA are large hydrophilic 
anionic polymers that are unable to cross the cell membrane without assistance.   Once inside 
the cell, plasmids have to travel through the cytoplasm and across the nuclear membrane into 
the nucleus to initiate gene expression. Plasmids move through the cytoplasm utilising the 
microtubule network and its associated end-directed motor dynein which in general is an 
ineffective process (60). Plasmid based methods do not generally replicate in mammalian 
cells and have a better safety profile when compared with other vectors. However plasmids 
possess considerably less gene delivery capability and, thereby potentially limiting future 
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clinical application. In order to improve transfection efficiency using plasmid DNA, chemical 
or physical strategies can be used. 
1.2.3.1.1 Chemical methods 
To function as a synthetic vector, chemical methods must protect DNA against nuclease 
degradation, effectively shepherd DNA across the target cell plasma membrane, through the 
hostile intracellular environment, and into the nucleus. The major chemical methods used to 
improve plasmid based gene delivery are calcium phosphate, cationic lipids and polymers. 
The major advantage of chemical methods are their simplicity, ease of production and 
relatively low toxicity. We discuss the mechanisms underlying these three approaches and 
compare their relative advantages and potential for clinical application. 
 
1.2.3.1.1.1 Calcium phosphate  
The use of calcium phosphate for gene delivery was developed by Graham and van der Eb in 
1973 and is currently one of the most commonly used in vitro gene delivery systems (61) 
because it is easy to use, cost-effective and a very safe technique. This technique utilises the 
formation of small, insoluble calcium-phosphate-DNA precipitates that can be adsorbed onto 
the cell surface and be taken up by cells through endocytosis. However, highly effective 
calcium-phosphate-DNA precipitates can only be generated under strict biochemical and 
physical conditions. Therefore, the transfection efficiency and expression levels are difficult 
to replicate in animal models. To counter these disadvantages, new methods based on the 
calcium-phosphate-DNA precipitation are being developed. Calcium phosphate 
nanocomposite particles encapsulating plasmid DNA are reported to demonstrate 
significantly higher transfection efficiency when compared to that of standard calcium 
phosphate transfection (62, 63).  
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1.2.3.1.1.2 Cationic lipids 
The use of cationic lipids for DNA delivery was pioneered by Felgner and colleagues (64) 
and the first cationic lipid synthesised for this purpose was N-(2,3-dioleoxypropyl) N, N, N-
trimethylamonium chloride (DOTMA).  Many novel cationic lipids have been developed 
since then, including N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-
sulfate (DOTAP), 3β[N-(N′, N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol)  
and dioctadecylamidoglycylspermine (DOGS) (65). The principle aim when using cationic 
lipids is the formation of DNA / liposome complexes (lipoplexes) (64, 66, 67). When 
hydrated, cationic lipids form liposomes, which when mixed with DNA, the positive charges 
at the liposome surface electrostatically interact with the negative charges on the phosphate 
backbone of the DNA to form DNA / liposome complexes (lipoplexes). The lipoplexes bind 
to the cell surface and enters by endocytosis. It then escapes from the endosome and 
dissociates to release the plasmid. The plasmid enters the nucleus and initiates gene 
expression. These lipoplexes significantly increase plasmid DNA transfection efficiency from 
5 % to more than 90 % in certain cell types. Numerous efforts have been made to optimise 
the transfection activity of cationic lipids.  The most important physicochemical properties 
dictating transfection activity is the cationic lipid structure. All cationic lipids have three 
common structures, a positively charged head group, a hydrophobic anchor and a linker 
connecting the head group and the hydrophobic anchor.  Many complex structures between 
DNA and cationic liposomes have been identified (68, 69), however the most important 
parameters affecting transfection activity of cationic polymers appear to be the particle size 
of the lipoplex and the charge ratio (amines to DNA phosphate ratio, + / -) (64, 67, 70). 
Transfection efficiency is attributed to efficient condensation of DNA by electrostatic 
interaction between the positively charged liposome and the negatively charged DNA, 
efficient interaction between a net positive charge of the cationic liposome / DNA complex 
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with the negatively charged cell membrane and effective intracellular DNA release owing to 
the fusogenic properties of cationic liposomes that form and destabilise the plasma 
membrane.  As a gene delivery method, cationic liposomes have many advantageous 
features, including their ease of preparation and production, providing several routes of 
administration, and at therapeutic doses they show non-toxicity and non-immunogenicity. 
However, significant success has been limited to in-vitro studies. Cationic lipids face 
significant challenges in-vivo. Deterrents include inactivation of lipoplex after systemic 
delivery, cell barriers preventing translocation into the target cell and intracellular 
inactivation of the plasmid mediated by factors that include low pH exposure and 
deoxyribonuclease (DNAse) activity. To help improve transfection, the addition of a ‘helper 
lipid’ like dioleoylphosphatidyl ethanolamine (DOPE) or cholesterol may improve stability 
and transfection efficiency in certain cell types (71).   
 
1.2.3.1.1.2 Cationic polymers  
Cationic polymers are a group of hydrophilic molecules that readily self-assemble with DNA 
and generate small tortoidal or spherical structures called polyplexes. Polyplexes are 
approximately 40-100 nm in size, depending on the polymer size and structure, DNA to 
polymer ratio and the type and concentration of ions in the buffer. The general type of 
polymers used are linear (polylysine, spermine and histone), branched and spherical. The 
most extensively studied and used cationic polymers are polyethyleneimine (PEI) and 
dendrimers. PEI may be a linear or highly branched organic polymer produced by 
polymerising aziridine. They have very high cationic charge density enabling the binding of 
anionic DNA within the physiological pH range to generate small condensates called 
polyplexes. Polyplexes can be manipulated to interact with a negatively charged cell surface 
to maximize DNA uptake. PEI, with every third atom in the polymer being amino nitrogen, 
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allows effective buffering of the sudden decrease in pH from the extracellular environment to 
the endosomal compartment. This feature is important for the protection of DNA as it travels 
to the nucleus. Dendrimers are a class of branched, spherical and starburst molecules. They 
differ in their initiator structure and in the number of layers or generations of building blocks 
in each molecule. The common initiators include ammonia as trivalent initiator and 
ethylenediamine as a tetravalent initiator. Polymerization takes place in a geometrically 
outward fashion, resulting in a branched polymer with spherical geometry and containing 
interior tertiary and exterior primary amines. Their precisely controlled size and shape allows 
the formation of more homogeneous and reproducible DNA complexes. Cationic polymers 
offer the advantage of simplicity, ease of production and relatively low toxicity as they will 
not elicit major immune responses or integrate into the host genome. 
 
1.2.3.1.2 Physical methods 
Physical methods use some form of physical force to overcome the physical barriers 
presented by tissues. Physical techniques include the application of energy waves to cells to 
create transient pores in the cell membrane, thereby permitting entry of plasmid without 
killing the cell.  The major physical methods developed for cancer therapy are direct needle 
injection, particle-bombardment or gene gun, hydrodynamics, electroporation and US.  
 
1.2.3.1.2.1 Direct needle injection 
Gene expression by the direct injection of plasmid DNA was first reported by Wolff et al in 
skeletal muscle 1990 (72). As previously discussed, the important variables dictating gene 
expression using this method are the factors affecting the transport of plasmid DNA from the 
outside of the cell, through the cytoplasm into the nuclear envelope. Gene expression using 
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this method is significantly lower than with other methods, however this method is likely to 
pose the lowest risk of toxicity or other unwanted effects.  In addition to skeletal muscle, 
gene expression after intra-organ injections of various organs including liver, heart and brain 
and intra-tumour injection has also been demonstrated.  The actual mechanism of plasmid 
DNA uptake by cells in vivo  is unknown. To improve gene delivery efficacy, the pre-
injection of various agents including bupivacaine and lignocaine prolong local concentration 
of plasmid DNA increasing the efficiency of direct injection.  The main disadvantages of 
direct injection are the low transfection efficiency, lack of cellular specificity and the brief 
expression in most tissues. 
 
1.2.3.1.2.2 Hydrodynamics 
The systemic delivery of plasmid DNA by needle injection results in poor gene expression in 
major organs because of the rapid degradation of the DNA by nucleases and the clearance by 
the mononuclear phagocytic system. Hydrodynamic gene delivery was developed to enable 
efficient gene delivery to internal organs. It involves a rapid injection of a large volume of 
plasmid DNA systemically. This method has been shown to induce high levels of gene 
expression in internal organs, with the highest level of expression observed in the liver. One 
of the major concerns about hydrodynamics-based gene delivery is its safety and invasiveness 
since it involves a rapid intravenous injection of an extremely large volume of plasmid DNA. 
Miao et al reported transient focal acute liver damage in animal studies after hydrodynamic 
treatment involving less than 5 % of the hepatocytes, which rapidly recovered with complete 
recovery, while Lie et al correspondingly showed a transient rise in the liver enzyme, alanine 
aminotransferase (ALT) after delivery (73). This rise was shown to occur at the earlier phase 
of treatment, suggesting that the increased permeability may account for considerable enzyme 
leakage from the hepatocytes. Taking account of these findings and the known intrinsic 
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ability of the liver for regeneration, the minor toxic effects and invasiveness would be 
acceptable for clinical application. The advantages of hydrodynamic gene delivery are its 
efficiency, reproducibility and the potential to apply organ restricted gene delivery. Wolff et 
al (74) was the first to report on the concept of organ-restricted hydrodynamics-based gene 
delivery, where hypertonic solutions of DNA were injected intraportally in murine models 
with transiently occluded hepatic veins. Zhang et al (75) demonstrated delivery via the portal 
and hepatic vein and bile duct while Eastman et al (76) demonstrated a catheter mediated 
hydrodynamics based delivery to individual lobes in rabbit models.   
 
1.2.3.1.2.3 Particle bombardment 
Particle bombardment first developed by Stanford and colleagues for plant cells involves the 
use of high pressure to drive DNA mixtures into the target tissue (77). The DNA mixture may 
be composed of gold or tungsten particles pre-coated with plasmid DNA. When fired, the 
gene-carrying particles enter the cytoplasm of the cells and the DNA is gradually released 
and then expressed. Factors affecting the efficiency of this method include the coating of 
DNA onto particles, particle size and the timing of the delivery. The major disadvantage of 
this method is the accessibility of target tissue.  Currently, this technique has largely been 
used for nucleic acid vaccination (78). 
 
1.2.3.1.2.4 Electroporation  
Electroporation (EP) is based on the principle that a short-pulsed electric field to a living cell 
causes a transient permeability in the outer membrane of the cell resulting in the cellular 
uptake of DNA (79). This permeability is manifested by the generation of pores across the 
membrane which closes in approximately 1 - 30 min after the field is discontinued, without 
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causing significant damage to the exposed cells.  It has been shown to work in a wide variety 
of cell types and by varying the electric field strength and the length of time the cells are 
exposed to the electric field, it is possible to improve transfection to any cell type. The 
negatively charged DNA molecule can enter through a concentration gradient that is 
facilitated by electrophoretic and electro-osmotic transport.  Electroporation has shown to 
increase gene expression in a range of tissues including liver, muscle, skin and solid tumours. 
In tumour delivery, plasmid DNA is injected into the interstitial spaces of the tissue and the 
required electric pulses are applied with needle or calliper-type electrodes. The advantages of 
electroporation include targeting expression as only the area of tissue exposed to the electric 
field will express the gene, the use of plasmid DNA is economical and simplifies gene 
preparation, the ability to apply large DNA constructs (80) and the relative safety to tissues. 
EP when compared to cationic polymers has been shown to result in reduced toll-like 
receptor 9 (TLR9) signalling and therefore a relatively low acute inflammatory response to 
plasmid DNA (81). An additional degree of specificity can also be achieved by using a 
tumour specific expression plasmid. EP has been tested extensively in preclinical melanoma 
models. Several of the preclinical therapies tested (Interleukin-12 and interleukin-2) have 
demonstrated therapeutic effect with minimal toxicity against melanomas and have now 
advanced to clinical trials. 
 
1.2.3.1.2.5 Ultrasound 
US mediated gene delivery was first reported by Fechheimer et al in 1987 (82). US (US) 
causes the transient formation of small pores of up to 100 nm in effective diameter with a 
half-life of a few seconds in cell membranes to enable the uptake of DNA. The biophysical 
effect of US most clearly implicated in the mechanism of reversible pore formation in the 
cytoplasm is acoustic cavitation. Applying US to liquid leads to the formation of vapour-
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filled bubbles or cavities. The formation and collapse of the US-induced bubbles is called 
cavitation. The collapse of these bubbles can be violent enough to transiently form pores on 
the cell membrane allowing DNA entry (83, 84). US exposure in the presence of microbubble 
echo-contrast agents have been shown to enhance acoustic cavitation and result in higher 
levels of gene expression (85). The advantages of US are it is non-invasive, well tolerated, 
with an exceptional safety record over a wide range of frequency and intensity and has high 
levels of public acceptability and understanding. Furthermore, there are available highly 
sophisticated, flexible, cost-effective and readily available diagnostic and therapeutic systems 
that can achieve site-specific transfer of US almost anywhere in the body.  
 
1.3 Clinical relevance 
1.3.1 Which method when?  
The suitability of various gene delivery methods for cancer gene therapy depends on a 
number of clinical variables, including the site of disease (breast, liver, bone, brain or lung), 
type of disease (primary, recurrence), extent of disease (clinical stage) and patient factors. In 
addition to clinical factors, the choice of method needs to be safe for general hospital use and 
commercially viable. In most cases, the site and type of disease will dictate the route of 
delivery (intra-tumoural, intravenous, intra-arterial, oral) while the duration and level of 
expression will depend on the type and extent of disease. In addition toxicity will affect 
patient compliance and immunogenicity will dictate the effectiveness of repeated dosing. 
This review looks at the potential application of gene therapy from a gene delivery 
perspective. It is based on our current knowledge of gene delivery and explores its relevance 
in the management of breast cancer.  
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1.3.2 Breast Cancer 
 
1.3.2.1 Localised Disease 
Breast cancer is the second most common cause of cancer related death in Irish women and 
the main cause of death in women ages 40 to 59. Despite advances in early detection and the 
understanding of the molecular bases of breast cancer biology, about 30 % of patients with 
early-stage breast cancer develop recurrent disease (10). Surgical excision followed by 
adjuvant therapies in the form of chest wall irradiation, chemotherapy and hormonal therapy 
remains the mainstay of  breast cancer treatment. While current strategies have proven very 
effective in the treatment of localised disease they offer challenges of their own. The breast, 
while being a superficial structure, lies in close proximity to the heart, lungs and major 
arterial and lymphatic vessels. Surgical excision of localised disease is in general a straight 
forward procedure. Following surgery, radiation of the chest wall and regional lymph nodes 
is performed, while hormonal treatments and systemic adjuvant chemotherapy is indicated in 
selected cases based upon hormone receptor status and prognostic risk factors. Despite the 
use of adjuvant therapies a substantial number of patients develop local recurrence due to 
residual disease. In addition, radiation and chemotherapeutics pose serious complications. 
Complications from radiotherapy include overlying skin damage, lung injury leading to 
diffuse scarring and fibrosis, cardiac toxicity and lymphoedema in patients who have 
undergone lymph node dissection (86, 87). Chemotherapy can cause life threatening 
conditions including acute myeloid leukaemia and myelodysplastic syndrome while 
hormonal therapies are associated with cardiac toxicity, osteoporosis, joint disorders, kidney 
and liver dysfunction (88, 89). Furthermore, a subset of patients present with locally 
advanced disease require preoperative cytoreduction in order to obtain maximum local 
control of disease to facilitate excision of the primary tumour (90, 91). While significant 
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improvements in local disease control have been seen with the use of systemic 
chemotherapeutics, these treatments are associated with serious side-effects. They may also 
fail to control local disease in a large number of cases due to a phenomenon known as 
primary resistance to therapy. Furthermore, breast conservation surgery is only possible in a 
selected group of cases and these patients are at significantly higher risk of local recurrence 
due to residual disease (10). Therefore, despite advances in adjuvant and neoadjuvant 
therapeutics, patients with localised disease still pose a significant clinical problem.  
The superficial location of breast tissue lends itself to the application of both biological and 
non-biological methods. Breast tumours may be approached by either using simple injection 
techniques under imaging guidance or via invasive surgery. Intratumoural delivery 
maximises initial delivery of vector into the tumour. Prolonged and sustained gene expression 
may not be an essential requirement for the eradication or cytoreduction of localised disease 
while long-term expression would most likely be necessary to prevent or contain disease 
recurrence in clinically indicated cases. RV are effective gene delivery vectors to a variety of 
cells and stable integration should provide long-term expression. However retroviral vectors 
integrate only into actively dividing cells. Breast tumours have been shown to have a 
heterogeneous population of both dividing and non-dividing cells. LV, a subset of RV, on the 
other hand are equally effective in both dividing and non-dividing cells (92). Breast tumours 
can range in size from a few mm to a few cm. For complete irradiation or effective 
cytoreduction large quantities of vector would likely be needed. Therefore, a major obstacle 
in using this vector is the cost of producing high viral titres for this purpose. Furthermore, the 
potential controversy and opposition to the use of vectors derived from HIV in the hospital 
setting cannot be overlooked. An alternative option is Ad, which demonstrates effective gene 
delivery in a large number of tumour types including breast cancer (92). While Ad does not 
offer prolonged transgene expression like RV, threshold expression is among the highest in 
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all gene delivery methods, and is reached rapidly in a variety of tumour cells including 
stromal and hypoxic tumour cells. Furthermore, Ad is relatively easy to produce in high titres 
and therefore economically viable, however, vectors must be administrated under level 2 
biosafety containment measures. The foremost consideration prior to clinical use is toxicity 
as has been tragically demonstrated in the past. The development of acute-phase toxicity is 
dependent on the dose of vector used, which is expected to be high in order to achieve 
complete tumour eradication. In addition, humoural immune response generated towards the 
vector will preclude multiple vector administrations. Therefore, regarding clinical 
application, the expression and safety profile would make Ad suitable for cytoreduction of 
locally advanced tumours prior to surgical resection as its cytotoxic effect is likely to be rapid 
but short-lived allowing for early surgical intervention following Ad application. AAV has 
the ability to effectively penetrate the stroma of solid tumours due to its small size, and offers 
a safer delivery option. While threshold expression is lower than Ad, transgene expression is 
stable with long term gene expression capability in both dividing and non-dividing cells. The 
major disadvantage with using AAV in this setting is the slow onset of gene expression. 
While the kinetic profile of this vector would preclude managing tumours in the acute setting, 
long term transgene expression would be suitable for the prevention of local recurrence. One 
of the drawbacks of intraoperative adjuvant therapy in the form of radiation or chemotherapy 
is tissue damage and poor healing leading to reduced cosmesis and the application of 
suboptimal treatment doses. In this regard, AAV expression kinetics would be suitable for 
intraoperative administration as the slow progression to achieve threshold expression would 
allow for tissue healing following surgical resection. The other main drawback of using AAV 
is that the small size of its genome significantly limits the amount of genetic material that it 
can carry and therefore limits therapeutic options applicable using this vector.  
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Non-viral gene delivery methods offer a safer but less efficient alternative strategy. Current 
plasmid based methods, due to overall gene delivery inefficiency, are unlikely to achieve 
complete eradication or offer cytoreduction properties. For solid tumours, plasmid based 
methods would likely require large quantities of DNA and energy to achieve gene expression 
levels comparable to those of viral vectors. The ability of plasmids to accommodate large 
DNA inserts and the  non-toxicity and non-immunogenicity properties of plasmid based 
delivery strategies may prove effective in patients with early breast cancer. While overall 
survival in these patients is high, a small subset develop disease recurrence, therefore, some 
form of local recurrence deterrent is warranted. Current deterrent strategies such as chest wall 
irradiation or chemotherapy have significant toxic side-effects which are very probable to 
negate their therapeutic benefits in this subset of patients. Plasmid based methods may be 
applied intraoperatively to sterilise the operative field following surgical resection. The 
devices used for electroporation and US can be easily modified for the hospital setting and 
the non-toxic and non-immunogenic nature of this method has little or no negative effect on 
wound healing, whilst potentially reducing risk of local recurrence from isolated tumour 
cells.                                                                                         
The lymphatic system is an important pathway for breast cancer spread. The breast has two 
major lymphatic basins, the axillary and internal mammary lymph nodes (93). Enlarged 
and/or suspicious lymph nodes are detected using regional ultrasonography, however, micro-
metastatic disease in lymph nodes require histological evaluation (94, 95). Sentinel lymph 
node biopsy is routinely used as an assessment tool for guiding loco-regional management of 
micrometastases in axillary lymph basins (96-98). The current recommendation for sentinel 
lymph node biopsy containing metastatic foci is axillary node dissection which is associated 
with significant complications including seroma, shoulder dysfunction, axillary web 
syndrome and lymphoedema (93, 99), while radiation of internal mammary basin is difficult 
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and increases cardiovascular mortality (100). For the potential management of lymph node 
disease by gene therapy, a promising strategy would be the use of a lymphatic targeting 
approach. The lymphatic system, while serving its function in cancer spread, is also a critical 
route for bacterial drainage making bacteria an ideal vector for treating lymphatic disease 
(101). Bacterial vectors can target tumours either by bactofection or through tumour-specific 
replication. Bacterial chemotaxis occurs towards chemo-attractant compounds which are 
present in conditions such as necrotic tissue, aberrant neovasculature or in immune 
sanctuaries (47, 102). However, these conditions are not expected to be present in lymph 
node basins containing micrometastases. Therefore, it is possible to hypothesis that bacterial 
vectors demonstrating bactofection such as Salmonella or L. monocytogenes may potentially 
be more effective for targeting nodal micrometastases. However, recent reports have 
demonstrated tumour-specific bacterial growth in small prehypoxic tumours, suggesting that 
hypoxia in necrotic centres may not be a vital component for tumour-specific growth (55). 
Intra-tumoural administration of bacteria will locate to lymphatic basins however, the 
required bacteria loads through this route is likely to be high due to tumour and systemic 
absorption. An alternative approach would be to deliver bacteria directly into the lymph 
channels (103). Intra-lymphatic administration will allow bacteria to reach and target 
micrometastases within lymph nodes. Furthermore, intra-lymphatic administration will result 
in the need for lower doses of bacteria and should reduce the adverse effects of systemic 
absorption.  
 
1.3.2.2 Metastatic Disease 
Metastatic disease is diagnosed at presentation in 1 - 5 % of women with breast cancer, while 
nearly 50 % of breast cancer patients will develop distant metastases (104-107). Patients with 
metastatic disease are unlikely to be cured of their disease by presently available treatment 
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strategies. Complete remission in patients with metastatic disease following current systemic 
treatments is uncommon and only a small percentage of those remain disease free for a 
prolonged period (108, 109). Survivors tend to be young and otherwise healthy women with 
oligometastatic disease. The five year survival rate in patients with metastatic disease remains 
poor. The poor long term survival rates have made the development of new treatment options 
particularly important for this subset of patients. More aggressive approaches, such as high 
dose chemotherapy or autologous stem-cell transplantation do not appear to improve overall 
survival (91, 110). It is evident that prolonged chemotherapy is associated with significant 
therapy-related toxicity with little or no benefit to overall survival. Where curative treatment 
by complete eradication of tumour burden is not possible, the focus of treatment shifts to 
symptom control and the improvement of quality of life. Factors which influence the choice 
of gene delivery method used to treat metastatic disease include the site and extent of 
metastasis, the number of metastatic sites and impending catastrophe. The most common sites 
of metastatic breast disease are the liver, bone, lungs and brain. The review looks at 
identifying the most appropriate gene delivery method and route of administration, taking 
into consideration characteristic anatomical and physiological  features of the affected organ 
together with clinical hallmarks of the disease.  
 
1.3.2.2.1 Liver 
Liver metastasis is by far the most common liver malignancy in the Western World. Nearly 
15 % of newly diagnosed patients with metastatic breast cancer have liver metastasis which 
may be the only site of distant disease (91, 105). Therapies to treat patients with hepatic 
malignancies have been investigated for many decades yet effective options for treating 
metastatic liver tumours remain few (111, 112). Resection of liver metastases has become the 
mainstay of curative management but only a minority of patients are candidates for surgery. 
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Since fewer than 20 % of liver tumours can be surgically resected, metastatic liver cancer is 
often fatal, with up to 90% of patients dying from liver failure (113, 114). Systemic 
chemotherapy with 5-fluorouracil (5-FU) modulated by leucovorin is the treatment of choice 
in patients unsuitable for surgical resection. It is associated with a major response rate in only 
a quarter of patients and median survival of 9 – 12 months (105, 107). To improve 
therapeutic efficacy, intravascular regional therapies by portal venous and hepatic arterial 
delivery of chemotherapy have been extensively studied (115) but have had little or no 
success in improving survival outcomes, while radiation therapy for liver metastasis has 
proven especially challenging as doses delivered must be limited to minimise damage to 
healthy liver tissue (111, 112). In view of the low response rate to 5-FU based chemotherapy 
and limited options for a second-line treatment, alternatives to systemic chemotherapy have 
been evaluated in patients with liver metastases.  
The liver is a complex organ in both anatomy and physiology. These characteristics present 
challenges, as well as offering opportunities when evaluating alternative treatments options.  
The liver is the largest organ in the body and regulates a wide variety of normal vital 
functions. Therefore, despite the ability to regenerate, extensive liver injury from non-specific 
therapeutics are poorly tolerated leading to multi-organ failure and eventual death. Gene 
therapy to isolated liver lesions can be delivered by injection under US guidance or by 
minimally invasive laparoscopic surgery. However, many patients with liver metastasis have 
multi-focal disease at time of presentation and consequently local treatment strategies are 
generally unsuitable. The most applicable treatment strategy in this case is systemic delivery. 
For systemic administration, methods that specifically target hepatocytes will avoid broad 
biodistribution and extrahepatic effects. Plasmid based methods have shown reduced 
efficiency following systemic delivery due to rapid degradation of plasmids by various 
nucleases present in blood extracellular matrix. While bacterial vectors have thus far not 
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demonstrated evidence of hepatic targeting, solid tumour targeting characteristics evident in 
several preclinical trials would suggest a similar response in metastatic liver disease (47, 53, 
55). In contrast, several viral vectors have shown hepatic transduction following systemic 
delivery. It is well established that intravenous administration of Ad results mostly in 
hepatocyte transduction because hepatocytes express high levels of the primary Ad receptor 
CAR (116, 117). However, high immunogenicity associated with Ad triggers a complex 
immune response, that leads to hepatotoxicity (117). This high immunogenicity also induces 
a long lasting cellular and humoural immunity that impairs subsequent re-administration. LV 
illicit little or no immune or inflammatory responses and have demonstrated long term 
expression through integration in hepatocyte preclinical models (118, 119). AAV serotype 8 
is highly liver tropic and AAV have shown preferential hepatic transduction in 
therapeutically relevant levels in vivo   following systemic delivery (120).  
The precision of gene delivery to the liver can be further regulated by the route of vector 
delivery.  The liver has a dual blood supply, receiving blood from the hepatic portal vein and 
hepatic artery. This unique anatomic feature provides systemic ports of entry either by the 
portal vein or hepatic artery for localised delivery of therapeutics. Intra-arterial administration 
demonstrates higher gene delivery efficiency as compared with the intraportal route, 
reflecting the fact that tumours within the liver are found to be supplied by the hepatic artery 
rather than the portal vein. Hydrodynamic gene delivery involves the rapid administration of 
a high volume of plasmid DNA through systemic ports and has shown high levels of gene 
expression in the liver (121). Under image guidance, sequential lobe-specific hydrodynamic 
gene delivery can be performed, whereby individual or multiple hepatic segments can be 
sequentially targeted with no little or no evidence of gene delivery in other organs (121). The 
advantages of using a plasmid based method is that plasmid is easy to make, is less 
immunogenic and can safely be modified for hospital use. One of the major concerns about 
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hydrodynamic-based gene delivery is hepatic toxicity as it involves a rapid portal delivery of 
an extremely large volume of plasmid DNA over a short period of time. However, liver 
injury using this technique is usually temporary and completely reversible. Other vectors 
including viral and bacterial can also be administered using systemic ports avoiding 
unnecessary systemic biodistribution. However, large liver lesions have demonstrated 
increasing resistance to viral transduction following intravascular delivery in preclinical 
models. The opposition to intravascular transduction has been attributed to the maturation of 
the blood-tumour barrier. The blood-tumour barrier is a physical barrier between blood and 
tumour cells. The thickness and impermeability of the vascular barrier increases as tumours 
increase in size and may serve to isolate tumour cells from systemic homeostatic mechanisms 
including the host immune system. Vasoactive compounds such as histamine and nitric oxide 
can augment the permeability of vascular endothelium. Histamine achieves this by opening 
intercellular junctions and creating endothelial pores, while nitric oxide, which normally 
regulates vascular integrity at physiological levels,  induces vasodilatation and microvascular 
leakage at therapeutic levels (122-124). Thus, the intra-arterial infusion of vasoactive 
compounds such as histamine or nitroglycerin, a nitric oxide donor, before vector 
administration has demonstrated the capacity to enhance transgene expression. 
 
1.3.2.2.2 Brain  
Despite surgical and medical advances, the prognosis for patients with brain metastasis 
remain grim (106, 125). In spite of major technical advances in neurosurgery such as 
microsurgery and stereotaxy, brain metastasis remain very difficult to resect due to their 
infiltrative nature and multifocal or multilobular presentation. (126). Radiation has shown to 
have little or no effect on long term survival while the major reason for chemotherapy failure 
is the difficulty of delivering therapeutic to the brain (106). Several effective therapeutics 
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cannot be used in brain metastasis, because the blood-brain barrier (BBB) prevents the 
transport of many systemically-delivered molecules into the brain. Gene delivery may be 
particularly useful in this situation for the delivery of therapeutics, which are otherwise 
difficult to deliver into the brain. While current therapeutics are a long way from achieving a 
cure, strategies providing symptom relief should be considered such as cytoreduction which 
would result in relieving raised intracranial pressure and reversing progressive neurological 
deficits. Using our knowledge of gene delivery methods and by exploiting specific central 
nervous system (CNS) delivery strategies we examine approaches for gene therapy to the 
brain.  
The intravenous administration of gene delivery vectors appears to be ineffective for CNS 
delivery due to the BBB blockage (127). The BBB is formed by tight junctions between the 
endothelial cells of the cerebral capillaries and blocks diffusion and entrance from the blood 
stream of even small vectors such as AAV to the brain parenchyma. Any systemically 
administered vector must penetrate the BBB to enter the brain. Lipid-soluble agents that can 
freely diffuse through the capillary endothelial membrane may passively cross the BBB. 
While plasmid DNA are not transported through this barrier, cationic lipids and polymers 
bind to plasmid DNA due to electrostatic interactions leading to hydrophobic collapse with 
compaction in the nanometer range (typically between 100-200 nm in diameter) so that 
complexes are small enough to be used to deliver plasmid DNA to the brain (128-131). While 
compaction protects plasmid DNA from nuclease degradation in systemic circulation, 
intravenous delivery can result in large molecular weight aggregates depositing in the 
pulmonary vascular bed, decreasing bioavailability to the brain. To reduce systemic loss, 
delivery can be administered intra-arterially into the internal carotid artery (127, 132). The 
main disadvantage to using cationic lipids and polymers in the brain is that highly charged 
complexes can inhibit important cellular processes such as cell survival signalling, leading to 
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substantial CNS toxicity (133). Current viral delivery strategies rely on direct invasive 
stereotactic injection that can circumvent the BBB; however, this technique is invasive and 
delivery is only limited to the CNS tissues surrounding the delivery tract and cannot be 
widely spread due to the potential risk of serious neurological damage. Convection-enhanced 
delivery administers viral particles actively though an infusion tube and has been shown to 
increase the distance of penetration after viral vector direct injection (134). However the 
insertion of the infusion tube is an invasive procedure and risk of infection is high, while 
gene delivery distribution remains relatively restricted (134). Certain agents including 
mannitol and microbubble-enhanced focused US (FUS) have shown to locally and temporally 
disrupt the BBB allowing increased penetration by viral vectors (135). FUS is capable of 
transcranial delivery and at present is the only known non-invasive method for localised and 
transient disruption of the BBB (135-137). An alternative route bypassing the BBB to the 
CNS that has been studied extensively is intrathecal or intraventricular, where therapeutics 
are administered directly into the cerebrospinal fluid (CSF) (138, 139). When compared to 
intravascular delivery using AAV in preclinical trials, intra-CSF administration results in an 
immediate high global CNS gene delivery with reduced peripheral organ distribution. The 
difficulty associated with intra-CSF administration is that only a small volume can be infused 
due to the resulting increase in intracranial pressure and the associated risk of intracerebral 
haemorrhage, CSF leak, CNS infection and neurotoxicity (139).  Intranasal delivery to the 
CNS is another novel technique under investigation. Intranasal delivery of HSV in preclinical 
models demonstrated widespread CNS distribution with less cytotoxicity when compared 
with intravenous and stereotactic delivery methods (140).  
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1.3.2.2.3 Bone 
Bone is the most frequent site for distant spread of breast cancer and the axial skeleton is 
predominantly affected (104). Patients with bone metastasis suffer from significant morbidity 
because of pain and skeletal related events (SRE) that occur due to tumour-induced osteolysis 
resulting in loss of the structural integrity of bone (104, 141). Radiation therapy is the most 
common treatment for bone metastases. However, if fractures are already present, radiation 
will not relieve pain and the high doses needed for treating disease will further impair the 
healing process. Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption 
and have been shown to prevent and delay SRE and to reduce bone pain (104). Nevertheless, 
in spite of aggressive treatment with bisphosphonates more than one third of these patients 
will develop further SRE within 2 years of initiating therapy (104). Clinical application of 
gene therapy to metastatic bone disease is not yet on the near horizon, although certain 
strategies have shown potential. There is substantial preclinical literature documenting 
successful delivery and intraosseous expression of genes using Ad, retroviral or plasmid 
based vectors (142, 143). These delivery methods can be used for both systemic and local 
transgene delivery. Systemic delivery aims to disseminate and express the transgene widely 
in the skeleton and is particularly useful in widespread bony disease. Bacterial vectors have 
the potential to home to bony metastasis after systemic administration (47, 55). Local 
delivery on the other hand introduces and expresses the transgene in a limited and defined 
area such as an isolated osseous lesion or pathological fracture (144). Local gene delivery has 
the additional advantage of minimizing side-effects in non-target organs, with little or no 
transgene expression outside the point of delivery unless initial transgene expression is 
exceptionally high (145). In addition to the delivery of cytotoxic genes, gene therapy may 
also be used to readdress the imbalance that occurs in metastatic bone disease between the 
action of osteoblasts and that of osteoclasts, resulting in net bone loss (141). Local delivery of 
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osteogenic transgenes, has shown great promise in a number of applications where it is 
necessary to regenerate bone (144-146). The stable and controlled delivery of growth factors 
and stimulation of osteoblastic new bone formation can potentially enhance and accelerate 
functional bone formation in diseased bone allowing application of higher doses of 
conventional therapeutics.  
 
1.3.2.2.4 Lung  
Breast cancer metastasis frequently occurs in the lungs, and is associated with a poor 
prognosis (91, 147). Isolated lung metastases have been reported to occur in 10 – 20 % of 
all women with breast carcinoma. Pulmonary metastasectomy can be carried out for multiple 
and bilateral disease (148). Regardless of complete resection, 5-year survival rate remains 
low (≤ 45 %) (147-149). In addition, conventional therapies such as chemo- and radiotherapy 
are ineffective, with nearly three quarters of patients who die of breast cancer having 
pulmonary metastases (147, 150).   
The lung is a complex anatomical and physiological organ. For discussion, the lung can be 
anatomically divided into the conducting airways (trachea, bronchi and bronchioles) and the 
parenchyma (gas-exchanging alveolar cells). The conducting airways branch from the hilum 
of the trachea towards the terminal airways and are responsible for the delivery of oxygenated 
air to the parenchyma. The parenchyma provides a very large surface area for blood-air 
interface and is highly vascularised from blood supplied by the pulmonary arteries (151). In 
addition the lung is also supplied with systemic blood for nutrition via the bronchial arteries 
which arise from the descending aorta. 
The lung is a particularly attractive organ for gene therapy due to potential accessibility 
through the airways and vasculature. Successful gene delivery to the lungs has been achieved 
in preclinical trials using direct injection, intranasal and systemic delivery. In the clinical 
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setting, gene therapy by direct injection can in theory be achieved by invasive surgery or by 
minimal access techniques such as video-assisted thoracoscopy (VATS) or transthoracic 
injection under imaging guidance. Bronchoscopy may be used for delivery to large 
conducting airways. Viral, bacterial and in particular plasmid based methods such as 
electroporation and US can be administered using these techniques. Electroporation has 
shown enhanced gene delivery, with reduced toxicity and inflammation when compared with 
cationic lipids in lung tissue (81, 152). The intranasal route by droplet or aerosol delivery 
provides a comparatively less invasive option. Viral and cationic polymers delivered by 
aerosol have demonstrated effective  and uniform distribution in preclinical trials (153). LV 
demonstrated long-term gene expression via aerosol delivery while the intranasal route was 
found to be superior to intravenous administration in Ad lung transduction (150, 154). While 
aerosol techniques have their advantages, certain clinical situations may preclude effective 
aerosol delivery such as bronchial inflammation due to pneumonia, lung collapse from 
tumour mass effect on main bronchus or large pleural effusions. In such situations, 
intravenous delivery may prove superior. Following intravenous administration, cationic 
lipids and polymers accumulate in the pulmonary vasculature because of the first passage 
effect. Successful gene expression was found in lung parenchyma after intravenous 
administration of cationic polymer and lipid based delivery methods (153). The duration of 
gene expression was biphasic in nature, with a initial dramatic but transient expression 
followed by a prolonged gene expression at a lower level. AAV vectors have shown potential 
for a delayed but persistent pulmonary expression while the systemic administration of 
Bifidobacteria have demonstrated gene expression in pulmonary metastatic nodules in 
preclinical models (55).    
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1.4 Discussion  
The leading cause of conventional treatment failure in clinically advanced disease is dose-
limiting toxicities leading to the development of treatment resistant tumour cells. For patients 
with disease recurrence following treatment, further management options are limited. The 
foremost challenge with current anti-cancer therapies is the lack of tumour cell specificity. 
The lack of specificity results in undesirable systemic side effects with little or no 
improvement in long term survival. Gene therapy has the potential to selectively target 
tumour cells and can be used either to deliver a therapeutic or to stimulate an immune 
response against tumour cells (155).  Additional advantages of gene therapy include the 
ability to express therapeutics for extended periods of time and to regulate therapeutic level 
both quantitatively and temporally. The primary goal of any gene delivery system is to 
achieve adequate gene delivery to the target cells with minimal damage to the host. 
Therapeutic efficacy is thought to be related to the tumour-associated vector load. The 
tumour associated vector load is dependent on the route of delivery. The review outlines gene 
delivery methods and routes of delivery available for the treatment of primary and metastatic 
breast cancer. We discuss gene delivery strategies for localised disease, cytoreduction 
techniques and micro or macro-metastatic disease in various organs. In this review we 
propose ways to enhance gene delivery by incorporating a strategy of selective disease based 
gene delivery. This approach aims to offer more effective and less toxic treatment by 
selecting gene delivery strategies based on clinical and disease characteristics.  
To achieve eradication of all tumour cells using a therapeutic approach, a very high level of 
transgene expression is likely be required. The duration of expression may not be clinically 
significant in this case. If complete eradication is unattainable, a containment strategy is the 
next best treatment option. For containment long-term expression of therapeutic is likely to 
be required to reduce the incidence of relapse and thus improving long-term survival. 
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However, a potential downside to using containment strategies is that treatment resistant cells 
will ultimately develop and overcome treatment. The best candidates for achieving long term 
transgene expression are integrating viruses such as RV and LV or AAV which offer 
persistent expression by remaining episomal. Certain non-viral constructs based upon 
transposons are also known to integrate and offer long term gene expression (117, 156). For 
life-threatening disease or when cytoreduction of locally advanced disease is required, short-
lived high bursts of transgene expression are best applied and can be achieved using vectors 
such as Ad. In patients with low risk of recurrence less toxic alternatives, such as plasmid 
based methods should be considered. For the treatment of metastatic disease, an organ 
specific approach needs to be taken, where the ideal delivery method is identified based on 
tissue tropism, route of administration and potential toxicity. Experimental evidence indicates 
that in addition to the vector used, the route of administration has a major influence on the 
transduction / transfection efficiency. By localising vectors at their desired site of action 
toxicity can also be reduced. The various factors that determine which route of administration 
favours a high transduction rate in a particular setting must be carefully considered. 
Optimizing the administration techniques with the vector used to maximise gene distribution 
and gene expression is an important step in selective disease based gene delivery. For 
targeting  multiple metastatic sites, vectors that are suitable for systemic delivery, with 
minimal side effects on healthy tissue are needed. While viral vectors have demonstrated 
tissue-selective expression, transduction with these vectors following systemic delivery are 
generally low and toxic effects remain. An attractive alternative may be the use of bacterial 
vectors demonstrating tumour specific replication. These vectors are generally safe and can 
potentially be given via the oral route. An additional option is to use multiple vectors  in an 
organ specific manner, where different gene delivery strategies are used for different organs.  
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When clinical translation is intended, additional factors, such as cost effectiveness, safety,  
intellectual property and public perception become very important. In addition to production 
cost, other factors need to be considered, such as cost development for hospital setting, safety 
precautions, ethical and public health approval for hospital use and general public acceptance. 
Depending on the vector and clinical features, there may also be advantages in terms of 
overall cost. Clinical grade viral vectors are demanding to manufacture and  need  to be used 
at high multiplicities of infection; both of these factors increase costs. Bacterial vectors, while 
considerably easier to manufacture and regarded as safer, still require biosafety measures for 
clinical use. Clinical application of gene therapy, especially for non-lethal diseases, such as in 
early breast cancer is hindered by its pervasive reputation for being unsafe and the belief that 
gene therapy is inherently more risky than conventional therapy. The application of vectors 
such as LV derived from HIV is unlikely to see clinical application in any but life-threatening 
diseases. Perceptions concerning the safety of adenoviral vectors have had to recover from 
the death of Jesse Gelsinger. Although gene therapy clinical successes so far have been 
limited to small numbers of patients it is hoped that the improved perception of gene therapy 
as a whole will enable greater and more sustained investment to supply the needed 
momentum for further development. Research into vector design needs to proceed in parallel 
with the clinical arena, where identification of obstacles to clinical gene delivery can inform 
the next phase of basic research. Symbiosis between the scientific and medical establishments 
will encourage rapid and significant improvements and innovations in gene / cell therapy 
technologies for anticancer treatments. In addition, a tailored personalised gene therapy 
protocol based on predictive factors and clinical features may become a reality.  
1.4.1 Limitations 
This review is based on a combination of preclinical and clinical trials and the authors 
recognise its inherent limitations due to this. In addition, transductional and transcriptional 
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viral targeting strategies, replicating viral vectors and the use of mesenchymal cells as 
delivery platforms were not discussed.  
1.5 Conclusions 
Gene therapy is an important advancement with the potential to revolutionise clinical care of 
cancer patients. However, current technologies to deliver genes are not sufficient to make 
gene therapy a one stop treatment strategy even under optimum conditions, let alone under 
stresses associated with malignancy. However, combining our current knowledge on vector 
characteristics with existing understanding of the clinical features of cancer may offer the 
best hope for moving forwards with gene therapy.  
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Chapter 2 
Preclinical Evaluation Of Gene Delivery Methods For The Treatment Of 
Loco-Regional Disease In Breast Cancer 
 
Sections from this chapter have been published as 
1. Preclinical evaluation of gene delivery methods for the treatment of loco-regional 
disease in breast cancer. Simon Rajendran, Deirdre O’Hanlon, David Morrissey, 
Tracey O’Donovan, Gerald C. O’Sullivan, Mark Tangney. Experimental Biology and 
Medicine 2011 Apr 1;236(4):423-34. PMID 21444371 
2. Ex vivo culture of patient tissue and examination of gene delivery. Simon 
Rajendran, Slawomir Salwa, Xuefeng Gao, Sabin Tabirca, Deirdre O'Hanlon, Gerald 
C. O'Sullivan, Mark Tangney Journal of Visualized Experiments, 2010 Dec 20;(46). 
PMID: 2132616 
3. Control and augmentation of long-term plasmid transgene expression in vivo in 
murine muscle tissue and ex vivo in patient mesenchymal tissue. David Morrissey, 
Jan P van Pijkeren JP, Simon Rajendran, Sara A Collins, Gareth Casey, Gerald C 
O'Sullivan, Mark Tangney. Journal of Biomedicine and Biotechnology. 
2012;2012:37984. PMID: 22811595 
 
  
  63 
Table of Contents 
 
Abstract __________________________________________________________________ 64 
2.1 Introduction ___________________________________________________________ 65 
2.2 Materials and Methods __________________________________________________ 68 
2.2.1 Human Tissue Samples ____________________________________________________ 68 
2.2.2 Tissue Slice Culture _______________________________________________________ 68 
2.2.3 DNA Constructs __________________________________________________________ 69 
2.2.4 Plasmid / Viral Delivery ___________________________________________________ 69 
2.2.5 Tissue Viability Assessment ________________________________________________ 70 
2.2.6 Histology and Immunohistochemical detection of Ki-67 Positive Cells _____________ 71 
2.2.7 Ex vivo and in vivo comparison of gene delivery ________________________________ 71 
2.2.8 Xenogen IVIS Imaging ____________________________________________________ 72 
2.2.9 Epithelial cell analysis of tumour slices _______________________________________ 72 
2.2.10 Cell type specific expression _______________________________________________ 72 
2.2.11 Statistics _______________________________________________________________ 72 
2.3 Results________________________________________________________________ 73 
2.3.1 Optimisation of tissue slice model system _____________________________________ 73 
2.3.2 Cell viability and characterisation of cultured tumour slices _____________________ 73 
2.3.3 Real-time luminescence imaging of ex vivo tissue permits assessment of gene delivery 
and expression over time _______________________________________________________ 75 
2.3.4 Comparison of ex vivo and in vivo  analyses ___________________________________ 76 
2.3.5 Examination of biological barriers to US gene delivery __________________________ 78 
2.3.6 Examination of biological barriers to Ad gene delivery __________________________ 80 
2.3.7 Validation of system using malignant and non-malignant tissues __________________ 82 
2.4 Discussion_____________________________________________________________ 85 
 
  
  64 
Abstract 
Preclinical results with various gene therapy strategies indicate significant potential for new 
cancer treatments. However, many therapeutics fail at clinical trial, often due to differences in 
tissue physiology between animal models and man, and tumour phenotype variation. Clinical 
data relevant to treatment strategies may be generated prior to clinical trial through 
experimentation using intact patient tissue ex vivo.  
We developed a novel tumour slice model culture system that is universally applicable to 
gene delivery methods, using a real-time luminescence detection method to assess gene 
delivery. Methods investigated include viruses (Ad and AAV), lipofection, US, 
electroporation and plasmid DNA. Viability and tumour populations within the slices were 
well maintained for 7 days, and gene delivery was qualitatively and quantitatively 
examinable for all vectors. Ad was the most efficient gene delivery vector with transduction 
efficiency > 50%. US proved the optimal non-viral gene delivery method in human tumour 
slices. The nature of the ex vivo culture system permitted examination of specific elements. 
Parameters shown to diminish Ad gene delivery included blood, regions of low viability and 
secondary disease. US gene delivery was significantly reduced by blood and skin, while 
tissue hyperthermia improved gene delivery. US achieved improved efficacy for secondary 
disease. The ex vivo model was also suitable for examination of tissue specific effects on 
vector expression, with Ad expression mediated by the CXCR4 promoter shown to provide a 
tumour selective advantage over the ubiquitously active CMV promoter.   
This is the first study incorporating patient tissue models in comparing gene delivery from 
various vectors, providing knowledge on cell-type specificity and examining the crucial 
biological factors determining successful gene delivery. The results highlight the importance 
of in-depth preclinical assessment of novel therapeutics and may serve as a platform for 
further testing of current, novel gene delivery approaches. 
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2.1 Introduction 
Breast cancer is estimated to account for nearly 27% of predicted new cancer cases in the 
United States and Europe this year (157, 158). Despite early detection methods and advanced 
conventional treatments, loco-regional recurrence rates can be as high as 13% (159). Nearly 
half of these patients will develop treatment resistant loco-regional disease, which is an 
independent prognostic factor associated with poor outcome (160). These figures clearly 
indicate the urgent need for novel therapies in the treatment of this disease and gene therapy 
is believed to offer exciting therapeutic approaches (161) and thus may prove suitable in 
altering the course of recurrent loco-regional disease. 
Various gene therapy strategies may be applicable for the targeted treatment of loco-regional 
disease. Clinical application however, depends on the ability to delivery sufficient genes to 
the target site. Six methods of gene delivery were examined in this study. While the use of 
other potentially more efficient and less immunogenic vectors, such as nanoparticles (162), is 
increasing, there are currently numerous ongoing human clinical trials utilising the methods 
described in this paper. The Ad vector, due to its exceptional gene delivery capability, has 
been the most widely used in preclinical and clinical trials (163). The concurrent success of 
non-viral gene delivery systems, including electroporation (EP) and Ultrasound (US) has also 
encouraged significant work in this field (164-166). Recent failure of promising gene therapy 
strategies in the clinical setting has highlighted the importance of testing strategies on the 
most stringent model available prior to entering clinical trials (167-169). The factors that are 
thought to play a major role in treatment failure are the unpredictable variation in tissue 
physiology between rodent and man, tumour heterogeneity and complex tumour phenotypes. 
This research quagmire has led to the demand for alternative models and has prompted the 
emergence of ex vivo model systems utilising intact human tissue. The tissue slice model 
system was first introduced by Krumdieck (170) several decades ago, however, its relevance 
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and potential in cancer research has only been realised of late. It involves the use of fresh 
human tumour tissue, cut into thin slices and maintained ex vivo, and represents a more 
clinically relevant primary model as it allows strategies to be tested on intact tissue. Several 
reports have utilised the tissue slice model of human tumours to study Ad mediated gene 
delivery (171-174); however, little is known about the effects of other gene delivery systems 
on human tumours and none of the current models offer the opportunity to investigate other 
gene delivery methods. Furthermore, previous reports on ex vivo models used analysis 
techniques requiring sacrifice of the tissue for quantification of gene expression. We 
introduce a novel ex vivo system with the capability of examining all delivery methods and 
offering real-time analysis of gene delivery. The universal application is achieved by utilising 
a slice thickness that does not limit nutrient and oxygen diffusion throughout the slice and 
allows for the physical delivery of genes by direct injection or the use of devices for 
electroporation and sonoporation. Furthermore, a thicker slice, which maintains all cellular 
components and diffusion gradients, would more closely represent the true intra-tumoural 
conditions of solid tumours.  
For measurements of ex vivo gene expression, we introduce a novel bioluminescence imaging 
technique based on the expression of luciferase, the light emitting enzyme of the firefly 
Photinus pyralis (175). This non-toxic detection system enables the sequential quantification 
of gene expression without sacrifice of tissue, allowing for measurement of duration of 
expression and thereby enabling assessment of vectors requiring longer incubation periods 
for maximum expression such as Adeno-associated virus (AAV) (176). For the investigation 
of vector efficacy, toxicity and target cell specificity we have optimised a dissociation 
technique, which provides representative cells from the entire slice for the accurate 
assessment of viability using automated cell counting and for identification of cell types by 
flow cytometric analysis. Using this model system we evaluate the efficacy of various gene 
  67 
delivery methods and the factors that limit or enhance gene expression in patient tumour 
samples. We also investigate the potential of tumour specific promoters to enhance tumour 
selectivity over normal tissue. This model would broaden our understanding of the biological 
factors that promote and hinder successful gene delivery to tumours and provide valuable 
insight for identifying novel gene delivery systems for the treatment of locoregional breast 
cancer. This would permit further assessment of the clinical relevance of new treatment 
strategies prior to entering clinical trial. 
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2.2 Materials and Methods 
 
2.2.1 Human Tissue Samples 
This study was approved by the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals and informed consent was obtained from the patients the day before surgery. Breast 
tumour samples were obtained from 80 patients undergoing wide local excision or 
mastectomy because of breast cancer, their age ranging between 35 and 75 years. The tissue 
was obtained from tumours greater than 2 cm in diameter as surgical waste from patients at 
the South Infirmary Victoria Hospital and Mercy University Hospital immediately after 
surgical resection. Liver tissue was obtained from three patients undergoing partial 
hepatectomy for metastatic liver disease. Colon tissue was obtained from three patients 
undergoing bowel resection for malignancy. 
2.2.2 Tissue Slice Culture 
Fresh tumour material upon collection was placed in collection media (Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with penicillin (200 IU/L), streptomycin (200 μg/L) 
and fungizone (250 μg/ml) at 4°C. Prior to slicing, tissue was washed with wash buffer 
(Phosphate buffered saline (PBS) supplemented with penicillin, streptomycin and fungizone. 
Slicing was performed aseptically using a Vibrotome (Leica, Germany). Tissue was held 
using Dermabond (Johnson & Johnson, UK) and the base discarded as waste. Slice thickness 
was set at 2000 microns and cut using a reciprocating blade at 22-26 rpm depending on the 
consistency of the tissue. Slices were incubated in 6-well plates (1 slice/well) containing 
culture media at 37°C with 5% CO2 in a humidified environment. 
http://www.jove.com/video/2378/ex-vivo-culture-of-patient-tissue-examination-of-gene-
delivery  
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2.2.3 DNA Constructs 
pCMV-luc plasmid, which expresses firefly luciferase under the transcriptional control of the 
cytomegalovirus (CMV) promoter, was purchased from Plasmid factory (Bielefeld, 
Germany). Replication incompetent recombinant Ad 5 particles under the transcriptional 
control of the CMV promoter and CXC chemokine receptor 4 (CXCR4) promoter were kind 
gifts from Prof. Andrew Baker, University of Glasgow, and Prof. David Curiel, University of 
Alabama respectively, and generated as described previously (171, 177). Infectious particle 
concentration was determined by plaque assay using the ViraPower
 
Adenoviral Expression 
Kit (Invitrogen, Dublin) according to manufacturer’s instructions. An AAV plasmid 
expressing firefly luciferase under the transcriptional control of the CMV promoter was 
constructed and purified as described previously (176).  
 
2.2.4 Plasmid / Viral Delivery  
Cell number for slice thickness was estimated at 8 × 10
6 
cells per slice based on an 80-cell 
thick slice (2000 μm) and 8-mm slice diameter. 50 μg of plasmid DNA in a volume of 50 μl 
(Buffer TE) was used for all non-viral methods. This was to ensure that plasmid DNA was 
not a limiting factor for gene expression, based on standard in vitro recommendations (1 μg 
per 1.9 × 10
5
 cells) DNA was injected directly into the breast tumour slices. After treatment, 
slices were incubated at 37 °C with 5 % CO2 in a humidified environment. Media was 
supplemented with serum after two hours.  
Viral Vectors: The titre employed for different particles was based on optimum particle 
concentration. For Ad 2.1 × 10
7
 infectious particles per slice (average of 2.6 infectious 
particles per cell) were administered. However, in AdCMV, this viral load saturated the 
Xenogen IVIS-bioluminescent detection system, and therefore 1 × 10
7
 infectious particles 
(1.25 viral particles per cell) per slice was used for all subsequent trials with this vector. AAV 
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titre employed was 1.1 × 10
8
 infectious particles per slice (13.75 infectious viral particles per 
cell) was based on experience with AAV used in murine therapeutic trials in our laboratory 
(176). 50 µl of viral particles AdCMV (1 × 10
7
), AdCXCR (2.1 × 10
7
), AAVCMV (1.1 × 
10
8
) were injected directly into the centre of the tumour slice.  
Electroporation: Plasmid DNA was injected into the centre of the slice. After 90 sec, pulses 
were delivered using a needle pair electrode. The tip of the electrode was carefully placed 
near the centre of the slice, by controlling depth of insertion relative to slice thickness. Pulses 
were generated using the Cliniporator (IGEA, Carpi, Italy) at 1 high-voltage pulse of 360 V 
followed by, 8 low-voltage pulses at 36 V (178). 
Sonoporation: Plasmid DNA was injected into the centre of the tumour slice. After 90 sec, 
low-intensity US was delivered for 5 min using a 1-MHz US transducer (CRM-1, UK) with a 
surface area of 5 cm
2
. The probe was held against the tumour throughout the duration of 
treatment. The parameters 1.0 W/cm
2
, 20 % duty cycle were used (179). 
Lipofection: 50 µg of plasmid DNA was combined with 25 µl Lipofectamine2000 
(Invitrogen, UK) (2:1) and incubated at RT for 5min. The mixture was injected directly into 
the centre of the tumour slice. 
 
2.2.5 Tissue Viability Assessment 
Viabilities of individual tissue samples were determined using propidium iodide (PI) by 
Nucleocounter (ChemoMetec, Ireland) or FACS. Tissue samples are dissociated into a single 
cell suspension using a combination of physical dissociation and enzymatic digestion. 
Briefly, the tumour slice is cut with a scalpel and incubated in culture media supplemented 
with Collagenase IV (1500 U per slice), Dispase (4.8mg per slice) and DNAse (0.01MU per 
slice) for 45 min at 37 °C. Dissociated cells were removed at 15 min intervals and passed 
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through a 70 μm nylon cell strainer (BD Falcon, UK). Both systems are based on the uptake 
of Propidium Iodide (PI) by non-viable cells. 
 
2.2.6 Histology and Immunohistochemical detection of Ki-67 Positive Cells 
For histological examination, tumour slices were fixed in 10% formaldehyde solution and 
embedded in paraffin.  Sections (4 μm) were prepared and for conventional histology were 
stained with Haematoxylin and Eosin (H & E).  In parallel sections, Ki-67 positive cells were 
immunohistochemically highlighted using the monoclonal antibody MIB1(MIB1, Dianova, 
DEA 505) as described by Gerdes et al (180).   
 
2.2.7 Ex vivo and in vivo comparison of gene delivery 
All animal experiments were approved by the Ethics Committee of University College Cork. 
Female MF1 nu/nu mice were obtained from Harlan Laboratories (Oxfordshire, England). 
For MCF-7 tumour induction, 1x10
6
 tumour cells, suspended in 200 µl of serum free DMEM 
were injected subcutaneously into the flank. When tumours reached 1 cm diameter; mice 
were anaesthetised using 100 μl intraperitoneal injection of PBS containing 1.5 mg ketamine 
hydrochloride (Veroquinol, Ireland) and 300 μg xylazine (Chanelle, Ireland) and tumours 
removed. Tumours were sliced, treated and analysed for gene expression at 24 h as described 
above. For in vivo experiments, mice were anaesthetised before viral, lipofectamine and 
plasmid vectors were slowly injected into the centre of the tumour. After 90 sec, this was 
followed by either US or electroporation treatment. In US treatment, high viscosity coupling 
gel (Aquasonic 100) was used to improve skin contact. 
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2.2.8 Xenogen IVIS Imaging 
Tissue slices were maintained in 6-well plates for analysis. 100 μl of 30 mg/ml firefly 
luciferin (Biosynth, Switzerland) was injected into the slices and 100 μl was added into 
media. After 10 min of incubation, slices were imaged for 5 min using an intensified CCD 
camera (IVIS Imaging System, Xenogen). For Whole Body Imaging of mice, 100 l of       
luciferin was injected intratumourally and 100 μl intra-peritoneally. 10 min-post luciferin 
injection, mice were anaesthetised and imaged for 3 min. All measurements were obtained 
using Living Image 2.6 application (181). 
 
2.2.9 Epithelial cell analysis of tumour slices 
Tumour slices were dissociated into a single cell suspension fixed using 70% ethanol and 
permeabilised using IFA-tx buffer (2 % FCS, 10mM Hepes, 0.1% Triton X-100, 0.1 % 
Sodium Azide and 150mM NaCl) buffer. Cells were incubated for one hour with pan-
cytokeratin (3 μg) antibody tagged with PE (clone C-11) (Abcam, UK). 
 
2.2.10 Cell type specific expression 
Slices were dissociated, fixed and permeabilised as described above. Cells were dual stained 
sequentially for one hour on ice with pan-cytokeratin antibody tagged with Phycoerythrin 
(PE) (3 μg), and primary luciferase antibody (10 μg) (clone Luci17) (Abcam, UK) and a 
secondary Cyanine 5 (Cy5) antibody (1:500) (Abcam, UK). 
 
2.2.11 Statistics 
Calculation of means, standard deviation (SD), and standard error of the mean (SEM) was 
performed using GraphPad Prism (V 3.0, San Diego, CA, USA). Statistical significances of 
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the differences between the individual groups were determined by using the two-tailed 
Student’s t-test for paired values. Differences with a p-value <0.05 were considered 
significant.  
 
2.3 Results 
 
2.3.1 Optimisation of tissue slice model system 
The optimum temperature for collection and storage of tissue was determined to be 4 °C (data 
not shown). At this temperature, viability was unaffected over a 12 h period and it prevented 
the occurrence of microbial infections before processing. The minimum thickness for 
accurate intra-tumoural gene delivery by direct injection and for the application of 
electroporation and sonoporation devices was 2 mm. The greatest transfection efficiency was 
found to occur in the absence of serum (data not shown) and consequently this was employed 
in all treatments. Serum was subsequently added 2 h after treatment for all methods. 
 
2.3.2 Cell viability and characterisation of cultured tumour slices 
To mimic in vivo conditions, efforts were aimed at maintaining slices in their constituent 
cellular components. In order to avoid stimulation of particular cellular populations, slices 
were maintained in standard culture medium. PI viability assays were employed to assess 
total cell viability at various time points after surgical resection prior to cultivation. The 
optimum harvesting time after surgical resection for breast tumours was within 30 min, with 
viability dropping by 80.2 % after 90 min (Figure 2.1a). All samples used for subsequent 
analyses were harvested within 30 min of resection from patients.  
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The efficiency of the culture method in retaining tissue viability over time was examined 
(Figure 2.1b). An initial decrease in viability observed at 24 h may be attributed to an 
adaptability period to culture conditions and therefore prior to all treatments, slices were 
incubated in culture medium for 2 h at 37 °C to ensure slice adaptation prior to treatment. 
Viability assays showed that slices were able to maintain 80 % of original viability for up to 
96 h (Figure 2.1b). The decrease in slice viability after 96 h is most likely due to a negative 
cell turnover (cell death > cell proliferation). Previously reported studies have only 
maintained ex vivo tissue viability for a shorter period of 4 days (172). In order to examine 
the uniformity of viability throughout the tissue section, intra-slice viability was assessed. No 
marked difference was observed between regions within the slice and there was a 
proportionate decrease in viability in all regions over time (Figure 2.1c). Flow cytometric 
analysis of epithelial cells indicated that a significant proportion of tumour cells (82.3 +/- 
12.3 %) were still present after 24 h of culture when compared with pre-cultured tissue 
(Figure 2.1d). Histological analysis at 0 and 24 h revealed no significant change in 
morphology or apoptosis as detected by H&E (ii). Proliferative cells were present at 0 and 24 
h detected by anti-Ki 67 staining (iii).  Thus, this culture system was capable of maintaining 
the desired viability and tumour component required for the application and assessment of 
gene delivery methods.  
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2.3.3 Real-time luminescence imaging of ex vivo tissue permits assessment of gene 
delivery and expression over time 
The optimised culture model was employed to assess and compare gene delivery systems. 
Breast tumour slices were administered CMV - firefly luciferase DNA cassette according to 
materials and methods using various gene delivery methods and expression analysed at 
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various time points post treatment. Parameters for various gene delivery methods were 
optimised in various cell lines and MCF-7 tumours in vivo . A method for real-time IVIS 
imaging of ex vivo tissue slices transfected with luciferase was developed. Luminescence per 
gene copy administered was determined and results are displayed in Figure 2.2a which 
represents maximum gene expression for various methods at their optimum time point. Ad 
has highest gene expression at 48 h, while AAV peaked at 120 h. The highest expression for 
lipofectamine was found at 72 h, while no further increase in gene expression was found after 
24 h for both US and EP unlike all other delivery methods. The results obtained with AAV, 
which requires the longest time for optimum expression (5 days) correlates with various 
published in vivo  time course studies. Ad proved the most efficient vector overall with US 
providing highest reporter gene expression among the non-viral methods in breast tumour 
tissue. 
 
2.3.4 Comparison of ex vivo and in vivo  analyses 
To assess consistency with the in vivo  setting, we performed in vivo and ex vivo MCF-7 
xenograft gene transfections / transductions using all methods. A xenograft model was used 
instead of spontaneous or induced models because of the relative ease in obtaining tumours of 
similar volumes.  Spontaneous or induced models would more closely represent the tumour 
state in patients in relation to organ specific physiology and immunogenicity. They however 
have slow and unpredictable growth rates and therefore require large numbers to obtain 
sufficient homogenous tumour experimental groups. The time point for maximum expression 
in vivo  for each method was used to measure luminescence. The pattern of relative 
efficiencies of methods in vivo  (Ad > AAV > Lipo > EP > US > plasmid) was reflected ex 
vivo except in the case of US which provided higher relative efficiency ex vivo. Both EP and 
Lipo performed better in the in vivo  setting. However, there was a marked reduction in the 
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efficiency of Ad and US as delivery methods in vivo . This suggests the activity of in vivo  
factors adversely affecting gene delivery and/or expression, which are absent in the ex vivo 
model for these methods (Figure 2.2b). 
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2.3.5 Examination of biological barriers to US gene delivery 
Among the non-viral methods examined here, US provided the greatest gene expression ex 
vivo in patient tumour tissue. In murine trials, the high level of US transfected gene 
expression was only seen ex vivo with significant reduction in vivo. To investigate the reasons 
for the dramatic differences between US results ex vivo and in vivo, (Figure 2.2b), we 
examined the involvement of physical factors that are not present ex vivo, as potential 
biological barriers to US gene delivery in vivo. We investigated the following physical 
factors; presence of blood, skin and temperature and tumour variables of tumour type, tumour 
stage (primary versus metastatic tumour) and tumour US wave penetration. 
The presence of whole patient blood acted as a barrier to all gene delivery methods, with the 
most significant effect on US as shown in Figure 2.3a. Separation of blood into cellular and 
serum components showed that US was only adversely affected by the cellular component of 
blood (data not shown). US may enhance gene delivery by either thermal or non-thermal 
effects. The thermal effect caused by US is due to the absorption of US waves. US 
application results in a 0.5 - 1.0 °C rise in tissue temperature, yet increasing tissue 
temperature to 39 °C, only moderately increased gene expression by plasmid delivery, which 
was still significantly lower than US (data not shown). However, combining hyperthermia 
(39 °C) with US improved transfection by 200 %, without affecting viability (Figure 2.3b). 
Increasing temperature beyond 39 C resulted in dramatic reduction in viability and gene 
expression per viable cell (data not shown).  
As evidenced by in vivo US-mediated delivery to mouse liver, overlying skin reduced 
transfection by 40 % when compared with direct contact (Figure 2.3c). The optimal distance 
from the US probe for highest transgene expression (Figure 2.3d) was also investigated. 
Maximal luminescence was seen in the tissue area 500 - 1000 μm from the US probe. The 
layer closest to the probe did not show significantly reduced viability following US 
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application (data not shown) indicating that the observed luminescence was due to maximum 
efficiency of gene delivery sonic waves 500 - 1000 μm from the US probe, rather than a high 
rate of cell killing outweighing DNA delivery in the tissue closest to the probe. US gene 
delivery was as effective in secondary nodal tumours compared with primary ductal tumours 
from the same patients (Figure 2.3e). However, gene expression was reduced in tissue slices 
originating from lobular tumours when compared with ductal tumours from three different 
patients (Figure 2.3f). 
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2.3.6 Examination of biological barriers to Ad gene delivery 
Ad vectors are extremely efficient gene delivery agents and target a wide host tissue range. 
However, various physical factors can limit gene expression. As previously mentioned, in 
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Figure 2.3a, blood is a barrier to all methods, reducing Ad gene expression by 50%. Solid 
tumours are associated with regions of reduced viability due to hypoxic conditions. Regional 
tissue viability can affect treatment in two ways, by reducing gene delivery and/or by its 
effect on gene expression. In our studies, viability was observed to have a linear relationship 
with plasmid DNA mediated transgene expression (data not shown). With Ad, reporter gene 
expression was unchanged at viability rates above 40 % of maximum viability, with 
significant reduction at viabilities below this threshold, suggesting saturation in luminescence 
readings or gene delivery above this limit (Figure 2.4a). Ad demonstrated good penetration 
of solid tumours, with comparable expression in all regions of the slice (Figure 2.4c). 
However, gene expression was significantly reduced (p=0.045) in nodal metastatic disease 
(Figure 2.4b) suggesting reduced transduction in metastatic tissue unlike observations with 
US (Figure 2.3e). Measurement of gene expression over time showed maximum expression 
at 48 h, correlating with in vivo  data, with 70 % reduction in gene expression at day 5 
(Figure 2.4d). 
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2.3.7 Validation of system using malignant and non-malignant tissues 
In order to further examine the culture and imaging system in a setting aimed at qualifying as 
well as quantifying reporter gene expression, we compared the tissue / cell selectivity of 
luciferase expression under the control of gene promoters with disparate expression profiles 
in malignant and normal tissues. While CMV is ubiquitously expressed, CXCR4 is 
considered to be differentially expressed in tumour cells (182-184). Ad vectors featuring the 
firefly luciferase gene under the control of either the CMV (AdCMV) or CXCR4 
(AdCXCR4) promoter were examined in breast tumour, normal colon and normal liver 
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tissues. Normal liver and colon was used rather than normal breast due to the fatty 
consistency of normal breast tissue making slicing impractical. When examined by 
bioluminescent imaging, AdCXCR demonstrated tumour tissue selectivity, with significantly 
improved normal to tumour ratio when compared with AdCMV (Figure 2.5a). To quantify 
transduction efficiency within tumour and normal tissue with both Ad vectors we optimised a 
method of gentle tissue dissociation using both chemical and physical means to isolate a 
representative population of cells. Ad mediated luciferase expression was examined by flow 
cytometry in cell suspensions derived from slices 48 h after treatment. We demonstrated 
transduction efficiency (% luciferase positive cells) of AdCMV (30.9 +/- 7.7 %) and 
AdCXCR4 (11.3 +/- 0.9 %) in breast tumour slices (Figure 2.5c and d respectively). This 
specificity was confirmed in analysis of liver samples, with 10.6 % (+/- 3.4) liver epithelial 
cells luc+ in AdCMV administered samples, compared with 0.6 % (+/- 0.4) in the case of 
AdCXCR4 (Figure 2.5e and f respectively) and in colon samples, with 20.3 % (+/- 8.4) 
colon cells luc+ in AdCMV compared with 0.77% (+/- 0.15) in AdCXCR4 (Figure 2.5g and 
h respectively). Graphical representation of transduction efficiency ratios in tumour, colon 
and liver is shown in Figure 2.5b. However, human tumours are composed of a variety of 
cells, of which only ~30% represent the tumour population. Hence, to assess cell type 
selectivity within the slices we co-localised transfected populations with an epithelial tumour 
cell marker, pancytokeratin. Analysis of tumour cell populations revealed that AdCXCR4 had 
a higher selectivity for expression in epithelial tumour cells [93.7 % (+/- 6.2) epithelial cells 
luc+; 6.25 % (+/- 3.46) non-epithelial cells luc+] when compared with AdCMVLuc [75 % 
(+/- 8) epithelial cells luc+; 25% (+/- 8) non-epithelial cells luc+] as shown in Figure 2.5i 
and j respectively. Figure 2.5k demonstrates graphical representation of epithelial cell 
transduction in tumours with both Ad vectors confirming selectivity of AdCXCR4 expression 
in tumour epithelial cells. 
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2.4 Discussion 
The major focus of this study was to determine whether ex vivo tumour slices could be used 
to compare various gene delivery methods using a real time bioluminescence detection 
system for quantitative assessment of gene expression in patient samples. This ex vivo model 
enables the assessment of gene delivery methods on the complex 3D architecture, tumour 
heterogeneity and phenotypic variation that is present in vivo . The maintenance of significant 
viability is crucial for ex vivo cultivation (185). In order to evaluate the suitability of this 
novel system, we studied the effects of culture conditions on tumour cell viability and 
variations in tumour cell populations over time. The tissue slices were maintained for up to 7 
days with sustained viability, ensuring appropriate response to various gene delivery 
experiments and allowing the use of methods requiring longer incubation periods for 
maximum expression such as AAV. There have been a number of publications over the last 
ten years on the use of ex vivo tumour slices with specific individual viral vectors (171, 172). 
However, only single methods were applicable using these models, valuable insights on 
tumour biology ex vivo and their effects on gene delivery were not fully explored. Our model 
uses a comparatively thicker slice of tumour tissue when compared with other model systems. 
Through optimisation, we achieved an important balance between ensuring adequate 
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diffusion of nutrients and oxygen to the inner regions of the slice and facilitating the physical 
delivery of genes by direct injection, the application of electroporation and sonoporation 
devices and enabling in-depth intra-slice analysis. Our approach of tumour dissociation for 
the analysis of PI uptake, cell markers and transduction efficiency allows for the examination 
of a representative, viable cell population in the relative proportions found in the intact 
tumours. This, we believe, gives a more detailed and accurate representation of the cells in 
the slices that may be unavailable in the intact tissue (186). Access to high quality screening 
in developed countries, has resulted in the detection of breast cancer at an earlier stage, 
leading to a decrease in the incidence of large tumours and thus less patient tissue available 
for research purposes. Even though our model uses a large slice of tumour, the 
bioluminescence detection system we have developed allows the accurate analysis of gene 
expression over time without sequential sacrifice of tissue, as with previous models, 
minimising wastage of valuable patient material. To allow for differences in tissue 
composition and variation in transfectability between patient samples, it was important to 
compare all methods on tissue from the same patient. Despite marked heterogeneity between 
patient samples, we found Ad to be the most effective vector overall, correlating with existing 
evidence in the field (187). The finding that US provided the optimal transgene expression 
for ex vivo human breast tumour slices among non-viral methods was surprising. When we 
repeated these experiments in MCF-7 xenografts, we found a similar trend in the ex vivo 
setting; however both methods had a significantly lower transfection efficiency in the in vivo  
setting. This suggested to us that physical conditions were inhibiting both methods from 
demonstrating their maximum transfection ability in vivo.  
The nature of the ex vivo system permitted the examination of specific physical factors 
individually, that can account for this reduction in gene delivery. Furthermore, comparing 
delivery to distinct histological types and stages of disease in breast cancer can be studied. 
  87 
The physical factors investigated were blood, regional viability, tumour penetration, skin, 
tumour type and temperature. Large bulky tumours, fluctuations in body temperature and the 
skin barrier are frequently encountered in the clinical setting. Solid tumours are known to 
possess a tortuous and leaky vasculature and can have significant variations in regional 
viability (188) while regional lymph nodes are the commonest site for metastatic spread in 
breast cancer. Our experiments show that blood, reduced viability, and nodal tissue are 
factors that adversely affect Ad gene delivery. The reduction of gene expression in nodal 
tissue is likely to be due to physical properties of nodal tissue rather than phenotypic 
variation in nodal tumour cells. Lymph nodes are composed of a fibrous capsule and a 
supporting meshwork of connective tissue and extracellular matrix (ECM) components which 
have previously been shown to reduce adenoviral gene delivery (189). The use of degradation 
enzymes of ECM components, such as hyaluronidases may improve Ad gene delivery to 
involved lymph nodes. In primary tumours, Ad demonstrated a transduction efficiency of up 
to 50%, and was potent at penetrating all regions of the slice. However, this efficiency was 
not accompanied by long term gene expression with >70% reduction in expression within 5 
days. Reduction in gene expression may be attributed to either cell turnover or cell death in 
the ex vivo tissue. In MCF-7 tumours, when comparing ex vivo with in vivo  gene expression 
there was significant reduction (50 and 74 % respectively) in gene expression in vivo  which 
may be linked to the presence of a systemic immune response in vivo  which is absent in an 
ex vivo model . US gene delivery offers good penetration of nodal tissue and a temperature 
rise of 2 °C greatly enhanced gene delivery. Expression is significantly reduced by the 
presence of overlying skin and blood, and it offers a reduced penetration of tumour slices. 
These findings indicate that Ad may be a better candidate vector for the targeting of large 
solid tumours. US offer a better safety profile albeit a less efficient alternative to Ad. Its 
greatest benefit may be in the treatment of superficial, small, and relatively avascular 
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involved nodes of the chest wall or axilla. The targeting of viable regions and a temporary 
blood-free field would improve transfection ability for all methods. The use of imaging 
modalities such as Colour Flow Doppler to identify neo-vascularity (190) and hence target 
viable regions and the application of vasoconstrictor agents to reduce blood exposure prior to 
treatment will improve gene delivery. In addition, heat delivery systems may improve US 
mediated treatment delivery. 
The model is not confined to tumour studies and allows for inter-tissue variations to be 
assessed. The chief safety concern with Ad use is activation of the inflammatory response 
syndrome (191). Slow intratumoural delivery of Ad and the use of polymeric delivery 
systems (192) reduces systemic dissemination. Yet, there can be significant viral loads 
systemically disseminated due to a delivery-induced convective transport into leaky vessels 
which leads primarily to accumulation in the liver (193). The predilection for liver 
accumulation in vivo  may be due to the detoxifying activity of the liver making it inherently 
prone to “capture” foreign particles. This unwanted effect from dissemination may be limited 
by the integration of unique promoters in viral vectors, which are highly expressed in tumour 
cells, with little or no expression in normal cells. Ad expressing luciferase under CXCR4 
control was found to improve tumour cell targeting with relative sparing of non-tumour cells 
in patient tumour slices, and moreover reduced gene expression in non-target tissue (liver 
slices). Comparison of tumour selectivity of the CXCR4 promoter evaluated by 
bioluminescence and FACS revealed good correlation with previous publications with regard 
to both tissue type and cell population. The tumour-cell selective transgene expression would 
suggest that Ad utilising the CXCR4 promoter would also support the systemic targeting of 
disseminated disease with minimal non-target effects and moreover allow early post surgical 
treatment. 
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Conclusions 
Our study demonstrates, for the first time that bioluminescence imaging of luciferase-
transfected patient tumour slices can be used for the assessment of gene delivery methods and 
to study physical barriers to gene delivery. Bioluminescent imaging provides a rapid, 
economical and simple method for monitoring gene expression. Furthermore, it offers an 
attractive alternative to animal trials and may provide a more accurate representation of 
patient response. A range of commonly employed gene delivery methods with potential for 
breast tumour therapy were examined with this strategy. While we did not examine other 
vector types in this study such as nanoparticles (194-196) or bacterial vectors (197), we have 
previously demonstrated bactofection using L. monocytogenes in ex vivo patient tumour 
tissue (197). It is therefore likely that the model system developed here is applicable to other 
vector types. In addition, a large number of patient tissue types may be examined using this 
model system including ovarian (197), colorectal (198) and mesenchymal tissue (199). 
Furthermore, the model is not confined to gene delivery assessment. The extended duration 
of culture period and 3D architecture of  this model makes it applicable to studies of novel 
gene therapeutic strategies where the interplay between tumour cells and the 
microenvironment are important. The findings from this study and potential relevance in the 
clinical setting highlight the importance of meticulous evaluation prior to entering clinical 
trial. 
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Chapter 3  
Adenovirus mediated transcriptional targeting of colorectal cancer and 
effects on treatment resistant hypoxic cells 
 
Sections from this chapter have been published as 
1. Adenovirus mediated transcriptional targeting of colorectal cancer and effects 
on treatment-resistant hypoxic cells. Simon Rajendran, Gerald C O’Sullivan, 
Deirdre O’ Hanlon, and Mark Tangney. Clinical Colorectal Cancer, 2013 
Sep;12(3):152-162. PMID: 23313233. 
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Abstract 
Colorectal cancer is the second leading cause of cancer-related mortality and frequently 
presents with locally advanced or metastatic disease. Ad vectors are important gene delivery 
agents as they offer efficient and broad tissue transducability. However, their ability to 
penetrate through multi-cell layers in colorectal cancers and maintain expression in colon 
tumour-related hypoxic conditions has yet to be analysed. Furthermore, their broad tissue 
tropism presents safety concerns. An ex vivo cultured patient tumour sample model was 
employed to examine Ad transduction of colorectal tumours. Results obtained from Ad 
delivery of the firefly luciferase (FLuc) reporter gene indicated that colon tumour tissue was 
more amenable to Ad transduction than other tumour histological types examined (breast and 
ovary). Ad transduction levels were significantly higher than a range of viral and non-viral 
methods examined in patient colon tissue. Control of transgene expression using the CXCR4 
promoter was examined as a strategy to confine expression to tumour cells. An Ad construct 
carrying FLuc under the control of the human CXCR4 promoter demonstrated low reporter 
gene expression compared with the ubiquitously expressing CMV promoter in normal colon 
and liver tissue while providing high expression in tumours, demonstrating a ‘tumour-on’ and 
‘normal-off’ phenotype in patient tissue. The effects of changing hypoxia on Ad-related 
transgene expression were examined in an in vitro model of hypoxic conditions relevant to 
clinical colorectal tumours. Reporter gene expression varied depending on the level of 
hypoxia, with significantly reduced levels observed with prolonged hypoxia. However, 
transgene expression was robust in the cycling hypoxic conditions relevant to colorectal 
tumours. This study provides novel, clinically relevant data demonstrating the potential for 
efficient gene delivery to colorectal tumours using Ad. 
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3.1 Introduction 
Colorectal cancer (CRC) is the third most common cancer in both men and women and the 
second leading cause of cancer-related mortality in both sexes in the United States and 
Europe (158, 200). Approximately 5–15% of newly diagnosed CRC cases present with 
locally advanced disease, while the liver is the most common site for metastatic spread (201). 
Extensive locally advanced or metastatic disease may require down-staging by chemotherapy 
to improve resectability. While current neoadjuvant chemotherapy regimens are efficient at 
down-staging disease, they are associated with significant side effects because of their 
relatively non-specific toxicity which can either delay the timing of surgical resection 
resulting in repopulation of tumour cells or increase postoperative complication rates (202). 
In this regard, gene therapy may serve as a novel neoadjuvant approach for the down-staging 
of locally advanced or metastatic disease prior to surgical resection. Various gene delivery 
methods have been developed to enhance tumour transduction efficiency (TE). Ad vectors 
are effective gene delivery vectors due to their efficient ability to target a wide range of cells. 
Preclinical trials have demonstrated the gene delivery capability of Ad in a number of 
different cancers (171, 174); however, its potential in clinical colorectal cancer has yet to be 
explored. In order to reduce toxicity to normal healthy cells from gene therapy, 
transcriptional targeting strategies can be employed. Transcriptional targeting involves 
regulating the expression of the gene of interest by utilising promoters, that maintain a 
‘tumour-on’ and a normal tissue-off’ status. A number of tumour selective promoters have 
been explored in the context of cancer gene therapy. The CXCR4 promoter has been shown 
to have an optimal profile of activity and specificity in various other tumour types (183, 203-
205). CXCR4 is also known to be over-expressed in colorectal carcinoma tissues when 
compared with normal tissues (206-208). Higher CXCR4 expression has also been found in 
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colorectal liver metastasis when compared to the primary tumour (209). In this study, we 
evaluate gene delivery using Ad and the transcriptional selectivity of Ad under the control of 
CXCR4 in an ex vivo human colorectal cancer model. We performed our studies on human 
tumour tissue as we felt this model system, though lacking a competent immune response, 
provides a reliable model for direct extrapolation to the clinical setting.  
We also explored the feasibility of gene delivery under conditions which mimic tumour 
hypoxia. Hypoxia is an important feature of solid tumours as a consequence of a structurally 
and functionally disturbed microcirculation and, in some cases, a reduced O2-carrying 
capacity of the blood due to tumour-associated anaemia (210). Hypoxic cells can also arise 
from perfusion driven changes in oxygen supply, resulting in rapid and reversible changes in 
oxygenation (211). Hypoxia has been related to the up-regulation of gene products that may 
promote tumour progression, by enabling tumour cells to adapt to nutritional deprivation or to 
escape a hostile environment. It is a well-established factor influencing treatment resistance 
to both chemo- and radiotherapy and is a prognosticator for poor survival (212, 213). While, 
stress response genes are up-regulated under hypoxia, the majority of cell metabolism is 
decreased, with a reduction in overall transcription and translation (214).  These effects may 
hinder gene delivery to hypoxic cells within solid tumours, and therefore the effects of 
hypoxia on Ad gene delivery warrant further investigation as the effective targeting of these 
cells may be an important predictor of treatment response in viral gene therapy. 
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3.2 Materials and Methods 
3.2.1 Human Tissue Samples and Tissue Slice Culture 
This study was approved by the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals and informed consent was obtained from the patients the day before surgery. Tissue 
samples were collected and cultured as described previously (46, 92, 215, 216).  Briefly, 
colon tumour samples were obtained from 30 consecutive patients undergoing bowel 
resection for colorectal cancer, their age ranging between 50 and 70 years. Patients who 
received neoadjuvant chemo-radiotherapy and those with small tumours with little surgical 
waste were excluded from the study. Type of surgical procedure was not considered here. 
The tissue was obtained as surgical waste from patients at the South Infirmary Victoria 
Hospital and Mercy University Hospital immediately after surgical resection. Liver tissue 
was obtained from three patients undergoing partial hepatectomy for colorectal metastatic 
liver disease. Fresh tumour material upon collection was placed in collection media, 
Dulbecco’s modified eagle’s medium (DMEM) (GIBCO, Invitrogen Corp., Scotland) 
supplemented with penicillin (200 IU / L), streptomycin (200 μg / l) fungizone (250 μg / ml) 
and gentamicin (125 μg / ml) at 4°C. Prior to slicing, tissue was washed with wash buffer, 
phosphate buffered saline (PBS) supplemented with penicillin (200 IU / L), streptomycin 
(200 μg / L), gentamicin (125 μg / ml) and fungizone (250 μg / ml). Slicing was performed 
aseptically using a Leica Vibrotome (Laboratory Instruments and Supplies, Meath, Ireland) 
as previously described (215, 217). Slice thickness was set at 2000 μm and cut using a 
reciprocating blade at 22-26 rpm depending on the consistency of the tissue. Slices were 
incubated in 6-well plates (1 slice / well) containing culture media at 37°C with 5 % CO2 in a 
humidified environment. Slices were injected with Ad constructs and maintained at culture 
conditions.  
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3.2.2 Vector constructs 
pCMV-luc plasmid, which expresses firefly luciferase under the transcriptional control of the 
cytomegalovirus (CMV) promoter, was purchased from PlasmidFactory (Bielefeld, 
Germany). Replication incompetent recombinant Ad particles under the transcriptional 
control of the CMV promoter (AdCMV) and CXC chemokine receptor 4 (CXCR4) promoter 
(AdCXCR4) were a kind gift from Prof. Andrew Baker, University of Glasgow, and Prof. 
David Curiel, University of Alabama respectively and generated as described previously 
(171, 177). Briefly, the Ad vectors encode the reporter gene, Firefly luciferase, regulated by 
CXCR4 or CMV promoter, which drives the reporter gene expression, inserted in the E1-
deleted region of the adenoviral vector backbone. For details of construction, see Zhu et at 
(182). The levels of luciferase expression related to these vectors reflects the activity of either 
CMV or CXCR4 promoters. Infectious particle concentration was determined in our lab by 
plaque assay using the ViraPower
 
AdExpression Kit (Invitrogen, Dublin) according to 
manufacturer’s instructions.  
 
3.2.3 Comparison of gene delivery methods  
Cell number for slice thickness was estimated at 8 × 10
6 
cells per slice based on an 80-cell 
thick slice (2000 μm) and 8-mm slice diameter. 50 μg of plasmid DNA in a volume of 50 μl 
(Buffer TE) was used for all non-viral methods. This was to ensure that plasmid DNA was 
not a limiting factor for gene expression, based on standard in vitro recommendations (1 μg 
per 1.9 × 10
5
 cells). DNA was injected directly into the colon tumour slices. After treatment, 
slices were incubated at 37 °C with 5 % CO2 in a humidified environment. Media was 
supplemented with serum after two hours. We did not use a range of multiplicity of infection 
concentrations (MOI). The titre of different particles was based on optimum particle 
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concentration. For Ad we used 2.1 × 10
7
 per slice (2.6 infectious particles per cell) per slice. 
However, in AdCMV, this viral load saturated the IVIS detection system, and therefore we 
chose 1 × 10
7
 infectious particles (1.25 viral particles per cell) per slice for all subsequent 
trials with this vector. 
Electroporation: Plasmid DNA was injected into the centre of the slice. After 90 sec, pulses 
were delivered using a needle pair electrode. The tip of the electrode was carefully placed 
near the centre of the slice, by controlling depth of insertion relative to slice thickness. Pulses 
were generated using the Cliniporator (IGEA, Carpi, Italy) at 1 high-voltage pulse of 360 V 
followed by, 8 low-voltage pulses at 36 V (178).  
Ultrasound: Plasmid DNA was injected into the centre of the tumour slice. After 90 sec, low-
intensity US was delivered for 5 min using a 1-MHz US transducer (CRM-1, Rich-Mar 
Corporation, Oklahoma, USA) with a surface area of 5cm
2
. The probe was held against the 
tumour throughout the duration of treatment. The parameters 1.0 W/cm
2
, 20 % duty cycle 
were used (179). 
Lipofection (Lipo):50 µg plasmid DNA was combined with 25 µl Lipofectamine2000 
(Invitrogen, UK) (2:1) and incubated at RT for 5min. The mixture was injected directly into 
the centre of the tumour slice (176).  
Viral vector transduction: 50 μl volumes of viral particles AdCMV (1 × 107) and AdCXCR4 
(2.1 × 10
7
) were injected directly into the centre of the tumour slice (92). 
 
3.2.4 Tissue Viability Assessment 
Viability of the individual tissue samples were determined using propidium iodide (PI) by 
Nucleocounter (ChemoMetec, Bioimages Ltd, Cavan, Ireland) or FACS as previously 
described (92). Briefly, tumour slices were dissociated into a single cell suspension using a 
combination of physical dissociation and enzymatic digestion. Optimisation experiments 
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were carried out using physical, chemical and a combination of both methods. The 
combination method had a slightly higher dissociation rate than chemical means, while 
physical methods alone had the lowest yield (results not shown) (217). The tumour slice is 
then cut with a scalpel and incubated in culture media supplemented with Collagenase IV 
(1500 U per slice), Dispase (4.8 mg per slice) and DNAse (0.01 MU per slice) for 45 min at 
37 °C. The dissociated cells are removed at 15 min intervals and passed through a 70 μm 
nylon cell strainer (BD Falcon, UK). Both systems are based on the uptake of PI by non-
viable cells. 
 
3.2.5 Bioluminescent Imaging 
Tissue slices were maintained in 6-well plates for analysis. 100 μl of 3 mg / ml firefly 
luciferin (Biosynth, Switzerland) was injected into the slices and another 100 μl was added 
into media. After 10 min of incubation, slices were imaged using the IVIS 100 Imaging 
system (Caliper Life Sciences, Cheshire, UK) and photons were counted for 5 min. 
Bioluminescence per slice was quantified using Living Image software (Caliper). 
Luminescence is represented as expression per gene copy administered.  
 
3.2.6 Flow cytometric analysis 
Tumour slices were dissociated into a single cell suspension using Collagenase IV (1500 U 
per slice) (Sigma-Aldrich, St. Louis, MO, USA), Dispase (4.8 mg per slice) (Sigma-Aldrich) 
and DNAse (0.01 MU per slice) (Sigma-Aldrich) for 45 min and then passed through a 70 
μm cell strainer (BD Falcon, UK). The cells were fixed using 70 % ethanol and permeabilised 
using IFA-tx buffer (2 % FCS, 10 mM Hepes, 0.1% Triton X-100, 0.1 % Sodium Azide and 
150 mM NaCl) buffer. Transduction efficiency (luciferase positive cells) was assessed by 
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staining cells sequentially for one hour on ice with primary luciferase antibody (10 µ) (clone 
Luci 17) (Abcam, Cambridge, UK) and a secondary Cyanine 5 (Cy5) antibody (1:500) 
(Abcam). For analysis of cell type specific expression, Cells were dual stained sequentially 
for one hour on ice with pan-cytokeratin antibody tagged with FITC (2 μg) (clone C-11) 
(Sigma-Aldrich), and primary luciferase antibody (10 μg) (clone Luci17) (Abcam,) and a 
secondary Cyanine 5 (Cy5) antibody (1:500) (Abcam). For Hif-1α analysis, cells were 
stained with anti-human Hif-1α (5 μg) antibody tagged with PE (clone 241812) (R&D 
systems, Abington, UK). For CXCR4 cell analysis, cells were stained with anti-mouse 
CXCR4 (5 μg) antibody tagged with phycoerythrin (clone 2B11) (eBioscience, San Diego, 
CA, USA).  
 
3.2.7 Modelling of hypoxic conditions in ex vivo tissue  
A system of changing oxygenation was developed to mimic the transient hypoxic conditions 
found in solid tumours. Hypoxic conditions were achieved by incubating slices in 20 μmol / 
ml cobalt chloride (Sigma-Aldrich). Three hypoxic states as previously described were 
studied. This analysed the effect of hypoxic or normoxic pre-conditioning, transduction and 
after transduction had on gene expression. The three hypoxic states included cycling (Hp-O2-
O2, O2-Hp-O2), prolonged (Hp-Hp-O2, O2-Hp-Hp) and chronic (Hp-Hp-Hp) hypoxia (214). 
Each state consisted of 3 cycles. Each hypoxic (Hp, in the presence of cobalt) or normoxic 
(O2, in the absence of cobalt) cycle was 8 h long. Briefly, tumour slices were incubated in the 
presence or absence of cobalt chloride for 8 h. Following the first cycle, tumour slices were 
washed in PBS and transferred to the second cycle where treatment with Ad in the presence 
of hypoxia or normoxia.  Following the second cycle, tumour slices were washed in PBS and 
incubated in the 3
rd
 cycle.  After completion of the 3
rd
 cycle at 24 h, gene expression was 
assessed using Bioluminescent Imaging. 
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3.2.8 Statistical analysis 
Calculation of means, standard deviation (SD), and standard error of the mean (SEM) was 
done in GraphPad Prism (V 3.0; GraphPad Prism Software Incorp., San Diego, CA, USA). 
The significance of the differences between the individual groups was carried out using the 
two-tailed Student’s t-test for paired values. Differences with a p-value < 0.05 were 
considered significant.  
 
3.3 Results 
3.3.1 Gene delivery to colorectal and other tumour tissue 
While there have been no previous gene delivery studies using patient colorectal tumour 
tissue, prior studies by us and others have demonstrated Ad vectors to be effective gene 
delivery vectors in a number of other types of patient tissue including breast and ovarian 
tumours (92, 174, 218). To assess the potential of Ad gene delivery in colorectal cancer, Ad 
gene expression in colorectal tumour slices was compared with both breast and ovarian 
tumour slices. There were significantly higher levels of gene expression per viral particle per 
viable cell in colorectal tumour slices when compared with both breast (p = 0.001) and 
ovarian (p < 0.001) tumour slices (Figure 3.1a). We also compared Ad with several gene 
delivery methods in tumour slices. The highest level of luciferase expression was found at 48 
h for all methods (data not shown). Ad was found to have significantly greater gene 
expression levels per gene copy per viable cell (p < 0.001) in patient tumour samples when 
compared with other standard gene delivery methods (Figure 3.1b). These results validate 
the clinical potential for Ad as an effective gene delivery vector for colorectal cancers.  
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3.3.2 Tumour-selective promoter-mediated restriction of transgene expression to 
colorectal tumour cells 
The tissue selectivity of Ad under the control of either the CMV or CXCR4 promoter was 
examined. While CMV is ubiquitously expressed, CXCR4 is considered to be differentially 
expressed in tumour cells (182-184). AdCMV or AdCXCR4 were examined in tumour and 
normal colon and normal liver tissues. The efficiency of Ad vector is likely to be different in 
cancer tissue from different patients. Therefore, tissue from each patient was used to conduct 
each entire experiment, and for every experiment conducted, colon cancer tissue samples 
from 3 different patients were used. To determine the tumour expression profile between 
AdCMV and AdCXCR4, colorectal tumour tissue were treated with both vectors, and 
expression detected by bioluminescent imaging at 48 h revealed no significant difference 
between both vectors in tumour slices (p = 0.285) (Figure 3.2a). Examination with normal 
tissue demonstrated that AdCXCR4 shows tumour tissue selectivity, with improved normal 
colon and normal liver to tumour ratio when compared with AdCMV (Figure 3.2b). The TE 
in tumour slices was determined by flow cytometric analysis. Tumour slices were dissociated 
using both chemical and physical means to isolate a representative population of single cells 
which were fixed and stained with anti-luciferase antibody. We demonstrated a comparable 
TE (% luciferase positive cells) of AdCMV (28.03 +/- 0.73 %) and AdCXCR4 (23.9 +/- 3.25 
%) (p=0.201) in colon tumour slices (Figure 3.2c). Graphical representation of TE ratios in 
tumour and normal colon and liver is shown in Figure 3.2d. Analysis of colon and liver 
samples revealed minimal transduction with AdCXCR4, while a greater number of normal 
cells expressing luciferase with AdCMV. For effective anticancer gene therapies, it is 
required that a high percentage of the tumour population are targeted by the vector. To 
determine the percentage of tumour cells transduced, luciferase positive cells were co-
localised with the tumour marker, pancytokeratin, and found that AdCXCR4 targeted a 
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higher percentage of tumour cells (67.4 ± 7.27 %) when compared with AdCMV (38.6 ± 5.83 
%) (p=0.037) (Figure 3.3a). To further validate tumour selective expression with CXCR4, 
gene expression in tumour-bearing slices was compared with tumour-free liver slices from 
patients with liver colorectal metastasis. Expression was found predominantly in slices 
containing tumour (p = 0.085) confirming restricted expression in tumour (Figure 3.3b).    
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3.3.3 Modelling of hypoxic conditions in ex vivo tissue  
A therapy that maintains therapeutic profile in hypoxic zones within solid tumours should 
improve the therapeutic to toxicity index and treatment outcomes when dealing with large or 
advanced tumours. Transgene expression levels may be modulated in response to hypoxia, 
and hence we investigated the effects on gene expression from the Ad vector in patient 
colorectal tissue slices, using the hypoxia inducer, cobalt. The key regulator of gene 
expression under hypoxia is hypoxia inducible factor-1 (Hif-1) (219, 220). Hif-1 is an oxygen 
sensitive transcription factor that accumulates under hypoxic conditions. Hif-1 is composed 
of two subunits, Hif-1α and Hif-1β. Hif-1α levels change in response to oxygen 
concentrations (220, 221). Cobalt mimics hypoxia by causing the stabilisation of Hif-1α (219, 
222, 223).                                                                                                                           
Hif-1α expression was measured by flow cytometry after culture of healthy liver tissue in 
culture medium supplemented with cobalt chloride. Normal liver tissue was used in this study 
because of the difficulty in obtaining large amounts of colorectal tumour tissue from the same 
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patient to conduct the optimisation experiment. Large quantity of liver tissue was available 
from each patient and liver tissue demonstrated tissue slicing consistency. The highest 
concentration of cobalt chloride (250 μmol / ml) which did not significantly affect tissue 
viability at 48 h was used (data not shown). Liver slices cultured in cobalt chloride were 
assessed for Hif-1α by flow cytometry. Incubation in cobalt chloride was found to lead to a 
progressive rise in Hif-1α levels over time, validating the use of cobalt chloride to mimic 
hypoxia in this setting. Peak Hif-1α levels were found at 6 h after exposure, suggesting that 6 
h is the minimum culture period required to achieve the hypoxic state (Figure 3.4a). A 
system of changing oxygenation aimed at mimicking transient hypoxic and chronic hypoxic 
conditions found in solid tumours (224, 225) was developed to further test the effect of solid 
tumour conditions on gene expression. 8 h was taken as time point for each hypoxic (Hp, in 
the presence of cobalt) or normoxic (O2, in the absence of cobalt) cycle. Once maximum 
hypoxia is reached, the tissue will remain in this hypoxic state. 8 h was chosen to allow 
comparison of data with other experiments, where gene expression was analysed after 24 h. 
Three hypoxic states were studied as previously described, cycling (Hp-O2-O2, O2-Hp-O2), 
prolonged (Hp-Hp-O2, O2-Hp-Hp) and chronic (Hp-Hp-Hp) hypoxia (214).  
 
3.3.4 Effects of hypoxia on Ad gene delivery and expression 
Ad gene expression was found to have similar levels in cycling hypoxia (Hp-O2-O2 
[p=0.642], O2-Hp-O2 [p=0.603]) and prolonged hypoxia (Hp-Hp-O2 [p=0.383], O2-Hp-Hp 
[p=0.439]) when compared with normoxic conditions, while chronic hypoxia (Hp-Hp-Hp [ 
p=0.239]) was found to have the most marked effect on gene expression (Figure 3.4b) with 
expression levels reduced by nearly 80%. The analysis of TE using Ad under the three 
physical conditions demonstrated a reduction in TE with increasing hypoxia. Significance 
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was found when comparing normoxia with prolonged (p=0.007) and chronic (p=0.003) 
hypoxia (Figure 3.4c). 
It is also known that some gene promoters including, CXCR4 are upregulated in hypoxic 
conditions (220). CXCR4 expression analysed by flow cytometery was found to increase in 
hypoxic conditions in the murine colon cancer cell line, CT26 (Figure 3.5a). When 
comparing AdCMV and AdCXCR4 in chronic hypoxic conditions, AdCXCR4 was found to 
have an improved hypoxic to normoxic ratio when compared with AdCMV (Figure 3.5b) 
suggesting that the CXCR4 promoter mediates higher gene expression over CMV under 
anoxia. To study the recovery of chronically hypoxic tissue and the effect on transgene 
expression, we analysed the effects of gene expression after reversing chronic hypoxia to 
normoxic conditions. Reversing chronic hypoxia to normoxic conditions demonstrated 
increased gene expression, though less than achieved in complete normoxia, expression was 
nonetheless nearly 30 times higher for both vectors than in chronic hypoxia (Figure 3.5c). 
This would suggest that re-oxygenation of chronically hypoxic regions in solid tumours may 
make them more susceptible to Ad gene therapies.   
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3.4 Discussion 
The treatment of advanced colorectal cancer remains an elusive predicament. The failure of 
conventional therapeutics to maintain remission has called for newer treatment options to be 
explored. We propose the use of gene therapy in colorectal cancer as an adjunct to surgical 
resection. Gene therapy offers the potential of a targeted therapy resulting in less non-specific 
effects. Successful gene therapy depends on the ability to transfer therapeutic genes to tumour 
cells. Adequate gene expression in tumour cells remains the main stumbling block in the gene 
therapy of cancer. Numerous gene delivery methods are under investigation with each 
method offering its own merits (226). Ad is an efficient gene delivery vector (227) for 
numerous cancers (217, 228) including breast and ovarian cancer and has in this study been 
shown to be more effective in colorectal cancers when compared with breast and ovarian 
cancer. Ad also demonstrated higher levels of gene expression when compared with other 
standard gene delivery methods including electroporation and lipofection with FACS analysis 
demonstrating TE > 30 %.  
To reduce the risk of nonspecific gene expression, transcriptional targeting offers promise. 
CXCR4, identified as a co-receptor for HIV-1, is a chemokine receptor functionally 
expressed on a multitude of tissues and cell types. CXCR4 and its ligand, CXCL12 (stromal 
cell-derived factor-1), play an important role in lymphocyte trafficking and recruitment, 
haematopoiesis and development processes such as organogenesis, vascularisation and 
embryogenesis. The binding of CXCL12 to CXCR4 (CXCR4 / CXCL12) initiates 
intracellular signalling through several divergent pathways including the Ras-MAPK 
signalling pathway which can result in a variety of responses such as chemotaxis, cell 
survival and/or proliferation, increase in intracellular calcium, and gene transcription (229, 
230). The up-regulation of CXCR4 in cancer cells leads to the activation of the Ras-MAPK 
signalling pathway resulting in increased proliferation, defects to apoptosis, invasiveness and 
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neovascularisation. The high expression levels of CXCR4 in cancer cells and low or absent 
expression levels in normal cells enabled the use of CXCR4 as a tumour- selective promoter 
to regulate Ad gene expression.  
When comparing AdCXCR4 with AdCMV, while gene expression was lower in tumour 
slices with AdCXCR4, we found relatively low expression in normal tissue (colon and liver), 
while levels in normal tissue with AdCMV remained high (Figure 2b). The TE in tumour 
slices was similar between both vectors (Figure 2c), while there was a significantly lower TE 
in normal tissue (colon [p=0.007] and liver [p=0.042]) when using AdCXCR4. Solid tumours 
are known to be composed of a variety of cells, of which only 30 - 40 % comprise tumour 
cells. Analysis of luciferase-positive cells demonstrated that AdCXCR4 targeted 67 % of 
epithelial tumour cells, a higher percentage of tumour cells within the tumour slice when 
compared with AdCMV which targeted only 39 % (Figure 3a). Previous reports have 
demonstrated therapeutic response using similar transduction efficiency (231). Therefore, 
selective targeting of tumour cells by AdCXCR4 will lead to more effective tumour 
destruction. The improved tumour to normal ratio will also reduce the non-specific effects to 
normal tissue, allowing normal tissue to recover to an adequate functional level. The selective 
tumour targeting will enable a higher therapeutic index when considering treatment using this 
vector. The tumour microenvironment is characterised by heterogeneous blood flow, 
resulting in varying regions of hypoxia. Hypoxia provides an environment directly facilitating 
chemo- and radio-resistance and also encouraging the evolution of phenotypic changes 
inducing permanent resistance to treatment (232).   
The one fundamental question remaining from Ad tumour delivery was the feasibility of gene 
delivery to hypoxic regions of solid tumours. Work on the effects of hypoxia on Ad gene 
delivery has only been demonstrated in vitro. Unlike previously published studies, we have 
analysed the effects of hypoxia on Ad gene delivery in patient tissue slice. We utilised a 
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cobalt-induced hypoxia model. Hif-1α levels are known to accumulate when exposed to 
proteasomal inhibitors, transition metals (e.g. cobalt), iron chelators or reducing agents (219, 
233). Cobalt mimics hypoxia by two mechanisms (31, 222, 223). It inhibits the hydroxylation 
of Hif-1α by binding to the iron-binding domain of Hif hydroxylase, inactivating the 
hydroxylase activity, while in the event that Hif-1α becomes hydroxylated, cobalt can also 
bind directly to the hydroxylated proteins to prevent the interaction between Hif-1α and 
pVHL, thereby preventing Hif-1α degradation (219). Cobalt was used instead of hypoxic 
chambers, as we aimed to study the isolated effects of hypoxia on gene delivery. Changing 
oxygen tensions will have local effects such as changes to pH, which in a dynamic in vivo 
system will be equilibrated, however in a static ex vivo model, these factors may account for 
effects on gene delivery. The luciferase bioluminescent detection system used for analysing 
gene expression is a very powerful, non-invasive method allowing rapid and sensitive 
longitudinal follow-up of gene expression in this model. The disadvantages of this model 
include the requirement of a substrate to enable light emission, utilisation of an oxidation step 
that requires molecular oxygen and the dependence of light signal on tissue depth. Therefore, 
this detection system will be less sensitive at measuring gene expression in thick tumour 
slices and in hypoxic states (234). Furthermore, oxygen tension may vary within solid 
tumours. Our model utilises a relatively thin tumour slice, non toxic substrate and cobalt 
chloride was used to mimic hypoxia having no impact on oxygen levels or tissue viability. 
The effects of Ad gene delivery to hypoxic cell in vitro have been previously studied in cell 
lines (214). However, effects on multi-cell layers or solid tissue and changing hypoxic 
conditions are to date unexplored. In this study, we highlight the importance of hypoxia as a 
potential barrier to gene expression. The fact that neither cycling hypoxia nor prolonged 
hypoxia, the major hypoxic states in solid tumours, had significant detrimental effects on 
gene expression is promising for future Ad gene therapy strategies for colorectal cancer. 
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However, chronic hypoxia was found to reduce gene expression by more than 80 %. This 
detrimental effect on gene expression was found to be reversible when slices were 
reintroduced to normoxia, with gene expression levels similar to those achieved in normoxic 
conditions. Chronically hypoxic cells are usually located in regions with inadequate and 
underdeveloped vascular bridges. Vascular normalisation using anti-angiogenic agents such 
as vascular endothelial growth receptor-2 antibodies and subsequent reduction in tumour 
hypoxia may be an alternative strategy to improve gene expression. The Coxsackie virus and 
Ad receptor (CAR) expression, which plays a crucial function in adenoviral cell entry, has 
been shown to decrease as tumours progress reducing efficacy of Ad vectors. This may be 
countered by using fibre mosaic Ad vectors, which utilise different receptors for cell entry 
(235). Ad can be delivered directly into the tumour mass limiting toxic effects on normal 
cells. Direct delivery can be achieved using endoscopy which is non-invasive, economical, 
well tolerated and relatively easy to perform (236).  
Gene therapy is hampered by poor gene transfer to the tumour mass via both viral and non-
viral vectors including adenoviral vectors. Many studies have explored the utilization of 
replicating Ad (oncolytic Ades) to enhance the viral distribution in the tumour mass, 
enhanced gene expression and oncolysis (237). There have been a few studies on the effects 
of hypoxia on gene expression and replication of Ad (238, 239). Hypoxia has been shown to 
reduce adenoviral replication in cancer cells by down-regulation of viral protein expression 
(239). A number of hypoxia-selective oncolytic Ad, generated by incorporating hypoxia-
responsive elements into synthetic promoters have been shown to be effective and safe (240). 
In conclusion, the Ad vector is a promising candidate for gene therapy in colorectal cancers. 
The AdCXCR4 vector demonstrates tumour selective expression with low normal and liver 
levels indicating that the CXCR4 promoter may allow tumour treatment with a low potential 
toxicity in normal tissue. The effective targeting in hypoxic conditions suggests that Ad may 
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offer a better strategy against the hypoxic component of human tumours than current 
therapeutics. A greater therapeutic index and enhanced hypoxic targeting may potentially 
result in better down-staging outcomes leading to improved surgical and hence treatment 
outcomes. 
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Chapter 4 
Targeting of Breast Metastases Using a Viral Gene Vector with Tumour-
selective Transcription 
 
Sections from this chapter has been published as  
1. Targeting of breast metastases using viral gene vector with tumour selective 
transcription. Simon Rajendran, Sara Collins, Jan P van Pijkeren, Deirdre O’ 
Hanlon, Gerald C O’Sullivan and Mark Tangney. Anticancer Research 2011 
May;31(5):1627-35. PMID: 21617219 
2. Murine bioluminescent hepatic tumour model. Simon Rajendran, Slawomir Salwa, 
Xuefeng Gao, Sabin Tabirca, Deirdre O'Hanlon, Gerald C. O'Sullivan, Mark Tangney 
Video Article. Journal of Visualized Experiments. 2010 Jul 17;(41). PMID:20689502 
 
  
  116 
Table of contents 
 
Abstract _________________________________________________________________ 117 
4.1 Introduction __________________________________________________________ 118 
4.2 Materials and Methods _________________________________________________ 121 
4.2.1 Cell culture _____________________________________________________________ 121 
4.2.2 Animals and tumour induction _____________________________________________ 121 
4.2.3 Induction of hepatic metastases ____________________________________________ 122 
4.2.4 Creation of splenic port ___________________________________________________ 123 
4.2.5 Production of AAV vectors ________________________________________________ 123 
4.2.6 Murine AAV treatments __________________________________________________ 124 
4.2.7 Human tissue samples ____________________________________________________ 125 
4.2.8 Bioluminescent imaging (BLI) _____________________________________________ 125 
4.2.9 Flow cytometric analysis __________________________________________________ 126 
4.2.10 Statistical analysis ______________________________________________________ 126 
4.3 Results_______________________________________________________________ 127 
4. 3.1 Preferential expression of AAVCXCR4 in subcutaneous and hepatic  MCF-7 tumours 
compared with non-malignant tissue ____________________________________________ 127 
4.3.2 Characterisation of intratumoural cell populations expressing transgene __________ 129 
4.3.3 Systemic delivery of AAVCXCR4 mediates tumour-specific transgene expression in 
murine livers ________________________________________________________________ 131 
4.3.4 Tumour-selective expression from AAVCXCR4 is maintained in patient tissue _____ 133 
4.4 Discussion____________________________________________________________ 134 
  
  117 
Abstract 
 
AAV vectors have significant potential as gene delivery vectors for cancer gene therapy. 
However, broad AAV tissue tropism results in nonspecific gene expression. We investigated 
the use of the CXCR4 promoter to restrict AAV expression to tumour cells, in subcutaneous 
mouse models of breast cancer and in patient samples, using bioluminescent imaging and 
flow cytometric analysis. We demonstrated higher transgene expression  in subcutaneous 
MCF-7 tumours relative to normal tissue (muscle) using the CXCR4 promoter, unlike a 
ubiquitously expressing CMV  promoter construct, with preferential AAVCXCR4 expression 
in epithelial tumour and CXCR4-positive cells. Transgene expression following 
intravenously administered AAVCXCR4 in a model of liver metastasis was detected 
specifically in livers of tumour bearing mice. Ex vivo analysis using patient samples also 
demonstrated higher AAVCXCR4 expression in tumour compared with normal liver tissue. 
This study demonstrates for the first time, the potential for systemic administration of AAV 
vector for tumour-selective gene therapy. 
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4.1 Introduction 
Breast cancer is the leading cause of cancer-related mortality in middle-aged women despite 
significant advances in conventional therapies (157). The prevalence of locoregional 
recurrence and distant metastasis can be as high as 13 % and 10 % respectively despite 
improvements in adjuvant treatment e.g. chemoradiotherapy and hormone therapy. The main 
stumbling block with both chemotherapy and radiotherapy is the induction of dose- limiting 
normal tissue toxicity, which reduce their clinical effectiveness. Liver metastases are present 
in 15 % of metastatic breast cancer patients and are the only site of distant disease in one-
third of these patients. Therefore, targeted treatment of localised liver disease would have the 
potential to improve outcome in a significant proportion of these patients. Currently, surgical 
resection is the treatment of choice for isolated liver disease. The liver’s unique anatomy 
presents numerous challenges when evaluating for surgical resection, resulting in fewer than 
20 % of liver tumours being suitable for surgical resection, and up to 90 % of unresected 
cases undergoing chemotherapy fail to maintain long-term remission and die from liver 
failure. These failings warrant new treatment options for this subset of patients. 
Gene therapy could potentially offer a safe and effective treatment modality in such 
patients. An ideal delivery system in patients with liver disease should offer effective 
transduction in the liver with prolonged gene expression restricted to infiltrative tumour cells 
only. Furthermore, it requires the capacity to be delivered by both local and systemic routes 
for isolated deposits and disseminated disease respectively, minimal expression in non-target 
organs and an acceptable safety profile. The use of an adeno-associated virus (AAV) 
approach has a number of features that make AAV an ideal vector for gene therapy strategies: 
it offers long-term gene expression, there is little or no cell-mediated immune response to the 
virus, and it is not associated with any disease (241). While AAV-derived vectors have 
shown promise in many clinical trials to treat a number of non-malignant conditions (33, 163, 
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168, 242), their use has not been examined widely in cancer settings (176, 228, 243). The 
suitability of AAV for tumour treatment lies in its ability to efficiently and stably transfect a 
wide range of cells, including dividing and non-dividing cells. It also has the ability to 
penetrate the stroma of solid tumours due to its small size and can offer an excellent safety 
profile combined with reduced potential for activation of inflammatory or cellular immune 
responses.  
AAV2 serotype was the first parvovirus to be isolated from humans and the first to be 
used as a vector for gene therapy application (244). AAV2 has a broad tissue tropism due to 
the wide expression of AAV receptors in all tissues (245). This would enable the targeting of 
systemically disseminated disease and, furthermore, AAV vectors have been shown to direct 
stable gene transfer and expression in hepatocytes. This feature makes them an attractive tool 
for treatment of liver metastatic disease. 
Currently, tissue targeting using AAV is mainly achieved by the localised delivery of 
treatments, and/or use of different, more recently identified serotypes with restricted tissue 
tropisms (155, 246). However, local delivery can only be achieved in limited situations such 
as for superficial deposits, skin and muscle, or may require invasive means for access. The 
most applicable treatment strategy for liver and distant metastasis is via systemic delivery. 
Yet the broad host spectrum of AAV may limit its systemic use due to transgene expression 
in normal tissue.  
This paper studies the use of transcription targeting for AAV to restrict transgene 
expression to tumour cells, thereby sparing normal tissue, an outcome that conventional 
therapeutic approaches have failed to achieve. Transcription targeting using specific 
promoters is one of the oldest and most widely used strategies for targeting gene therapy (3, 
9). Tumour-specific promoters (TSP) restrict the expression of genes of interest to tumour 
cells (182). Numerous TSPs have been applied in preclinical studies, including alpha-
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fetoprotein, carcinoembryonic antigen, survivin, CXCR4 and osteocalcin (3). However, their 
use has not been investigated in AAV as widely as in Ad. CXCR4 is a chemokine receptor 
that has been shown to be expressed at high levels in many types of cancer, including breast 
cancer, but is repressed in normal tissue (183, 247). CXCR4 regulates the growth of primary 
and metastatic tumours and tumour cells are believed to adopt the expression of chemokine 
receptors to facilitate metastatic spread through chemokine gradients (184, 248). 
The aim of our study was to develop a strategy to increase efficiency and specificity 
of tumour gene delivery. This paper incorporates the use of the CXCR4 as a TSP in an AAV 
vector and investigates its tumour selective potential in models of both primary and 
metastatic breast cancer. 
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4.2 Materials and Methods 
 
4.2.1 Cell culture 
The human adenocarcinoma breast cancer cell line, MCF-7 (ATCC, Manassas, VA, USA) 
was maintained in Dulbecco’s minimal essential Medium (DMEM) (GIBCO, Invitrogen 
Corp., Scotland) supplemented with 10% foetal calf serum (FCS), 100 U / ml penicillin, 100 
µg/ml streptomycin, 2 mM L-glutamine and sodium pyruvate and grown at 37 °C in a 
humidified atmosphere of 5 % CO2. 
 
4.2.2 Animals and tumour induction 
All murine experiments were approved by the Ethics Committee of University College Cork. 
Mice were obtained from Harlan Laboratories (Oxfordshire, UK). They were kept at a 
constant room temperature (22 
o
C) with a natural day/night light cycle in a conventional 
animal colony. Standard laboratory food and water were provided ad libitum. Before 
experiments, the mice were afforded an adaptation period of at least 7 days. Female mice in 
good condition, without fungal or other infections, weighing 16 – 22 g and of 6 – 8 weeks of 
age, were included in experiments. For routine tumour induction, 2 × 10
6
 tumour cells, 
suspended in 200 µl of serum-free DMEM were injected subcutaneously into the flank of 
female MF1nu/nu mice. The viability of the cells used for inoculation was greater than 95 % 
as determined by Nucleocounter (ChemoMetec, Bioimages Ltd, Cavan, Ireland ). Following 
tumour establishment, tumours were allowed to grow and develop and were monitored twice 
weekly. Tumour volume was calculated according to the formula V=(ab
2) Π/6, where a is the 
longest diameter of the tumour and b is the longest diameter perpendicular to diameter a. 
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When tumours reached approximately 100 mm
3
 in volume, the mice were randomly divided 
into experimental groups. 
 
4.2.3 Induction of hepatic metastases 
Isolated MCF-7 liver tumours were induced in MF1 nu/nu mice as described elsewhere (165, 
249). Briefly, mice were anaesthetised using 100 μl intraperitoneal injection of Phosphate 
buffered saline (PBS) containing 1.5 mg ketamine hydrochloride (Vetoquinol, Dublin, 
Ireland) and 300 μg xylazine (Chanelle, Loughrea, Ireland) and placed on a heating pad. The 
abdominal skin was disinfected with 10 % w/w iodinated povidone antiseptic skin cleaner 
(Videne, Ecolab, Leeds, UK). A 1 - 1.5 cm incision was made in the left subcostal margin. 
The abdominal muscles were divided, the peritoneum opened and the abdomen entered. The 
spleen was gently mobilised and the mid-body of the spleen divided between two 4 / 0 Vicryl 
ligatures (Ethicon, Johnson & Johnson, Berkshire, UK) placed between splenic vascular 
pedicles, such that each had its own vascular pedicle and was still in contact with the portal 
circulation. MCF-7 cells (5 × 10
5
) were inoculated into one hemi-spleen, which was removed 
10 minutes later. The other hemi-spleen was returned intact, leaving the mouse with half an 
immunologically competent spleen. Mass closure of peritoneum and muscle was performed 
using 4 / 0 PDS (Ethicon, Johnson & Johnson, Berkshire, UK) and the skin closed using 4 / 0 
Prolene (Ethicon, Johnson & Johnson, UK). Animals were fed a moistened diet for 24 hours. 
Carpofen (5 mg / kg, Norbrook laboratories, Newry, UK) was used for postoperative 
analgesia. Animals were observed for the development of disease and treated at day 7 post 
inoculation. 
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4.2.4 Creation of splenic port 
The use of a splenic port for hepatic delivery has been described previously (250). Liver 
metastases were induced as described above. For this model, the intact hemi-spleen was 
transposed to a subcutaneous position while carefully preserving its vascular pedicle. The 
defect in the abdominal wall was reapproximated using 4 / 0 PDS to hold the spleen in 
position, over which the skin was closed. Postoperative recovery was as above. The 
subcutaneously placed hemi-spleen was easily visible and palpable for direct delivery into the 
portal circulation. 
 
4.2.5 Production of AAV vectors 
A schematic representation of the relevant elements of the vector constructs utilised is shown 
in Figure 4.1. AAVCMV expressing firefly luciferase was generated (176). Firefly 
luciferase-expressing AAVCXCR4 vector was generated as follows:  pDriveCXCR4LacZ 
plasmid was purchased from Invivogen (Cayla SAS, Toulouse, France). The CXCR4 
promoter DNA sequence was PCR amplified using primers designed with M1uI and EcoRI 
restriction overhangs, (forward- M1uI5’ CATACGACGCGTAGTTGACAATTAATCAT 
CGGC3, reverse:EcoRI 5’CGAATTCGTAACCGCTGGTTCTCCAAGAT3’) and cloned 
into pAS (AAV-luc). This CXCR4 promoter DNA sequence was inserted upstream of the 
firefly luciferase gene. Thus the levels of luciferase expression reflect the activity of the 
CXCR4 promoter. Clone sequence was validated by sequencing (MWG Biotech, Ebersberg, 
Germany) and restriction enzyme analysis.  AAV particles were generated using the AAV 
Helper-Free System (Stratagene, Agilent, Dublin). AAV particles were purified using Virakit 
AAV Purification Kit (Virapur, San Diego, USA) as per manufacturer's instructions. 
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4.2.6 Murine AAV treatments 
All treatments were carried out under general anaesthesia in Class 2 containment hoods. Viral 
vector particles were administered in a volume of 50 μl for all delivery routes. In 
subcutaneous tumour and muscle delivery, 1 × 10
8
 infectious particles were injected slowly 
into the centre of the subcutaneous tumour or into the quadriceps femoris muscle of the lower 
limb. For direct intrahepatic delivery, a right subcostal incision was made and 1 × 10
8
 
infectious particles were injected under direct vision into the liver capsule. Due to difficulty 
generating large viral titres, we developed the splenic port model as direct intravenous access to the 
liver via the portal circulation. Following tumour cell delivery and excision of the inoculated 
hemispleen, the untreated hemispleen is used to create a port that can be used for hepatic 
portal delivery. The hemispleen is transposed to a  superficial position in a subcutaneous 
pocket carefully preserving its vascular position. For splenic port injections,  1 × 10
8
 
infectious particles AAV vectors were injected into the subcutaneous hemi-spleen, allowing 
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direct delivery of vectors into the portal circulation and therefore into the liver. 
http://www.jove.com/video/1977/murine-bioluminescent-hepatic-tumour-model 
 
4.2.7 Human tissue samples 
This study was approved by the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals and informed consent was obtained from patients. Tissues were collected and 
cultured as described previously (215, 251). Briefly, breast tumour samples were obtained 
from patients undergoing wide local excision or mastectomy because of breast cancer. 
Tumour free liver tissue was obtained from three patients undergoing partial hepatectomy for 
metastatic liver disease. Fresh tumour material upon collection was placed in collection 
medium DMEM supplemented with penicillin (200 IU / l), streptomycin (200 μg / l) and 
fungizone (250 μg / ml) at 4 °C. Slicing at 2000 µm was performed aseptically using a Leica 
Vibrotome (Laboratory Instruments and Supplies, Meath, Ireland). Slices were incubated in 
6-well plates (1 slice / well) containing culture media at 37 °C with 5 % CO
2
 in a humidified 
environment Slices were injected with AAV after 6 hours of incubation and maintained at 
culture conditions.  
 
4.2.8 Bioluminescent imaging (BLI) 
For in vivo imaging, mice were anaesthetised and were injected intraperitoneally with 100 μl 
of an aqueous solution of luciferin (3 mg / ml) and placed under the chamber of the CCD 
camera system of the Xenogen IVIS 100 Imaging system (Caliper Life Sciences, Runcorn, 
Cheshire, UK) and photons were counted for 3 min. Regions of interest were identified and 
quantified using LIVING Image software (Caliper Life Sciences, Runcorn, Cheshire, UK). 
For ex vivo imaging, tissues of interest were excised, placed in 6-well tissue plates with 150 
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μg/ml D-luciferin in PBS and imaged for 3 min. Luminescence is represented as expression 
per gene copy administered.  
 
4.2.9 Flow cytometric analysis  
Subcutaneous tumours were dissociated into a single cell suspension using Collagenase IV 
(1500 U per tumour) (Sigma-Aldrich, St.Louis, MO, USA), Dispase (4.8 mg per tumour) 
(Sigma-Aldrich, St.Louis, MO, USA) and DNAse (0.01MU per tumour) (Sigma-Aldrich, 
St.Louis, MO, USA) for 45 min and then passed through a 70 μm cell strainer (BD Falcon, 
Dublin, Ireland). The cells were fixed using 70% ethanol and permeabilised using IFA-tx 
buffer (2% FCS, 10 mM Hepes, 0.1% Triton X-100, 0.1 % Sodium Azide and 150mM NaCl). 
To assess the transfection efficiency (luciferase positive cells), cells were stained sequentially 
for one hour on ice with primary luciferase antibody (10 μg) (clone Luci17) (Abcam, 
Cambridge, UK) and a secondary Cyanine 5 (Cy5) antibody (1:500) (Abcam, Cambridge 
UK). For CXCR4 cell analysis, cells were stained with anti-mouse CXCR4 (5 μg) antibody 
tagged with phycoerythrin (clone 2B11) (eBioscience, San Diego, CA, USA). For epithelial 
cell analysis, cells were stained with pan-cytokeratin (3 μg) antibody tagged with PE (clone 
C-11) (Abcam, Cambridge, UK). 
 
4.2.10 Statistical analysis 
Calculation of means, standard deviation (SD), and standard error of the mean (SEM) was 
carried out in GraphPad Prism (V 3.0; GraphPad Prism Software Incorp., San Diego, CA, 
USA). The significance of the differences between the individual groups was carried out 
using the two-tailed Student’s t-test for paired values. Differences with a p-value <0.05 were 
considered significant. 
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4.3 Results 
 
4. 3.1 Preferential expression of AAVCXCR4 in subcutaneous and hepatic    
MCF-7 tumours compared with non-malignant tissue 
A human breast cancer (MCF-7) murine model was used to study tissue specificity of AAV 
vectors under the control of CMV (AAVCMV) and CXCR4 (AAVCXCR4) promoters. To 
establish that it was possible to detect both AAVCMV and AAVCXCR4 in muscle and 
tumour, and also to determine the expression ratio between tissues over time, subcutaneous 
MCF-7 tumours and muscle for each mouse were treated with direct administration of 
AAVCMV or AAVCXCR. AAV vector transduction is often slow due to the necessity of 
conversion of the single-stranded genome into double-stranded DNA. Previous work by us 
and others has demonstrated a delay in AAV-related expression following administration; 
therefore, experimental animals were not imaged prior to day 7 post vector delivery (155). At 
day 7, AAVCMV-related luminescence was observed in both muscle and tumour with a 
relative expression ratio of 50 ± 5% in muscle when compared with tumour (Figure 4.2a). At 
day 10, AAVCMV expression remained relatively unchanged in tumour, while there was a 
further increase in expression in muscle (58 ± 25 %), surpassing that of the tumour. In the 
case of AAVCXCR4-related luminescence, tumour levels were markedly higher than in 
muscle, with expression ratios of 10 % in muscle relative to tumour at both days 7 and 10, 
although differences did not reach statistical significance. 
 To assess expression levels in a model for metastatic disease of the liver, confined 
hepatic tumours were established by intrasplenic administration of MCF-7 tumour cells. At 7 
days post tumour induction, particles were injected directly into the liver. AAVCXCR4 
demonstrated tumour to normal expression ratios in liver tumours similar to those observed in 
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subcutaneous tumour animals (Figure 4b). AAVCXCR4 muscle expression was 54 % that of 
tumour at day 7, although not statistically significant. Conversely, AAVCMV muscle 
expression was over 20-fold higher than tumour levels.  
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4.3.2 Characterisation of intratumoural cell populations expressing transgene 
To determine transduction efficiencies and to identify cell populations targeted by both viral 
vectors, subcutaneous MCF-7 tumours were treated with either vector at day 10 post tumour 
induction. Treated tumours were harvested and dissociated into single cells as described 
previously (46). The transduction efficiency (luciferase-positive cells) of AAVCMV was 
greater than that of AAVCXCR4 (Figure 4.3a). To examine the correlation between reporter 
gene expression and a CXCR4 protein-positive phenotype, luciferase-positive populations 
were co-stained with anti-CXCR4 antibodies. Results shown in Figure 4.3b demonstrate that 
AAVCXCR4 shows transcriptional selectivity for CXCR4-positive cells (43 ± 5 %) when 
compared with AAVCMV (25 ± 5 %) within solid tumours.  
Solid tumours are known to be composed of distinct subpopulations including tumour 
epithelial cells, stromal cells and immune-associated cells. When luciferase-positive cells 
were co-stained with an epithelial-specific antibody (pancytokeratin), there was a higher 
percentage of pancytokeratin-positive (tumour) cells expressing luciferase in tumours treated 
with AAVCXR4 (67 ± 5 %) when compared with tumours treated with AAVCMV (32 ± 7 
%) (Figure 4.3c), demonstrating that AAVCXCR4 has transcriptional selectivity for CXCR4 
positive and epithelial tumour cells within solid tumours, while AAVCMV, although 
achieving higher expression levels, mediates transcription in all cell types. 
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4.3.3 Systemic delivery of AAVCXCR4 mediates tumour-specific transgene 
expression in murine livers 
The ideal cancer therapeutic strategy would selectively target malignant cells throughout the 
body, while having minimal effect on healthy cells. To examine the possibility for AAV to be 
used in a systemic cancer therapeutic strategy (previously unreported), mice bearing localised 
hepatic tumours were administered either vector through a splenic port. While luminescence 
from AAVCMV was significantly higher than that from AAVCXCR4, AAVCMV expression 
was concentrated at the site of administration (splenic port), unlike AAVCXCR4, where 
expression was detected only in the liver (Figure 4.4a). This pattern was confirmed by ex 
vivo BLI of the excised tissues (Figure 4.4b). The tumour-specific nature of AAVCXCR4 
was further confirmed by examining its expression in both hepatic tumour-bearing and 
tumour-free animals. AAVCXCR4 gene transcription was up-regulated in livers bearing 
tumour, with only baseline levels evident in the livers of tumour-free mice (Figure 4.4c). Ex 
vivo analysis confirmed that gene expression of AAVCXCR4 was confined to tumour bearing 
organs (Figure 4.4d). 
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4.3.4 Tumour-selective expression from AAVCXCR4 is maintained in patient 
tissue 
To assess the translational aspect of using CXCR4 as a tumour specific promoter in an AAV 
vector, the transcriptional patterns of AAVCMV and AAVCXCR4 were assessed in ex vivo 
cultured normal (liver) and tumour (breast) patient tissue samples (n = 3) and BLI carried out 
five days post transduction. Analysis revealed AAVCXCR4 expression was 4 times greater in 
tumour tissue than in normal liver tissue, although not statistically significant, while 
expression of AAVCMV was comparable in both normal and tumour tissue (Figure 4.5). 
This confirms the tumour selectivity of AAVCXCR4 in patient tissue, a fact which, when 
combined with the systemic murine data from this study, supports the concept of utilising 
AAVCXCR4 as a reliable tumour-targeting systemic vector for treatment of metastatic 
cancer.  
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4.4 Discussion 
The concept of developing gene delivery vectors that localise gene expression to tumour sites 
via systemic delivery is important for the advancement of cancer gene therapies. A 
systemically delivered targeted therapy allows biodistribution of therapeutic to metastatic 
disease in distant organs, with the advantage of reduced toxicity and improved therapeutic 
index and with a convenient and generally well-tolerated administration. This work provides 
proof of concept for the possibility of selective tumour targeting via AAV vectors following 
systemic delivery. We demonstrated reduced expression of AAVCXCR4 in normal tissue in 
which standard AAV vector (AAVCMV) is strongly expressed, which translated to a 
reduction in non-specific transgene expression. The AAVCXCR4 vector demonstrated 
efficient tumour-selective expression when locally administered to subcutaneous tumours and 
normal tissue (muscle). Population analysis by FACS showed that AAVCXCR4 
preferentially targets epithelial tumour and CXCR4-expressing cells in subcutaneous MCF7 
tumours, while the CMV promoter demonstrated majority expression in non-tumour and non-
CXCR4-positive cell types. 
AAV is known to mediate long-term expression in both normal and tumour tissue, 
unlike other widely used gene delivery vectors such as Ad, which only maintains minimal 
gene expression within days after delivery. Comparison of the expression kinetics of CMV 
with CXCR4 revealed that the CXCR4 promoter retained high expression in tumours while 
maintaining low expression in normal tissue for a period of up to 10 days, unlike AAVCMV. 
AAVCMV expression in tumours decreased by 65 % from day 7 to day 10. CMV promoter 
activity has previously been demonstrated to be silenced in tumour cells via methylation of 
‘foreign’ (microbial) DNA CpG sequences (252-254). Therefore, even though the CMV 
promoter may provide higher expression levels initially, use of a native mammalian promoter 
sequence like that of CXCR4 is likely to provide long-term expression.  
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Our intravenous delivery experiments in the hepatic model demonstrated enhanced 
gene expression for AAVCXCR4 in tumour-bearing livers with minimal expression in 
tumour-free livers. Several serotypes of AAV exist and corresponding tissue tropism varies 
considerably (246). The AAV2 serotype examined here is known to transduce a wide range 
of tissue types, including liver and muscle, albeit at a lower efficiency than other serotypes 
more specific for individual cell types. Therefore, use of an AAV serotype with a high 
tropism for the target tissue would be expected to produce efficiencies higher than reported 
here for AAV, in addition to providing a further level of selectivity in terms of vector safety. 
In particular, it has been demonstrated that AAV8 has higher efficiency for delivery to liver, 
while AAV1 and AAV6 to lung (244, 255). Therefore, employment of other serotypes, or 
pseudotyping (cross-packaging AAV2 DNA with other serotype capsids) may further 
improve expression in liver and other distant metastatic sites (256).  
CXCR4 expression represents an ideal tumour-selective system, as it has been shown 
to be up-regulated in breast tumour cells and suppressed in normal epithelial cells. 
Furthermore, this up-regulation of CXCR4 may contribute to metastatic progression through 
chemokine networks (184, 248). Therefore, the use of CXCR4 as a TSP would potentially 
enable selective targeting of CXCR4-positive tumour cells which are developing or already 
possess the potential for metastasis. Furthermore, ex vivo studies with patient tissue have 
demonstrated the tumour-selective nature of AAVCXCR4 over AAVCMV, confirming the 
translational potential of this vector. 
Due to their distinctive properties, AAV vectors have the potential to play a 
significant role in the advancement of cancer care. Here we have demonstrated an AAV-
based tumour targeting strategy using a tumour-selective promoter strategy. The 
transcriptional targeting approach displays significantly improved tumour to normal 
transgene expression ratio, allowing for the efficient targeting of AAV vectors to cancer cells 
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and the sparing of normal tissue in both subcutaneous and metastatic liver tumours using both 
local and systemic delivery routes. Intra-tumoural analysis emphasised the specific tropism 
for tumour cells. This study demonstrates the tumour-targeting flexibility which AAV-based 
vector systems offer and the ability to administer AAV systemically and achieve a high level 
of systemic tumour targeting. This vector strategy stands to play an important role in 
targeting distant, inaccessible, or undetected metastatic disease. 
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Chapter 5 
 Conclusions and future direction  
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5.1 Conclusions 
Cancer remains a leading cause of morbidity and mortality despite better 
understanding of cancer causation and progression. Current anticancer regimens are 
associated with non-specific cytotoxicity leading to treatment failure due to serious toxic 
effects to normal tissue and the development of treatment resistant disease. Gene therapy has 
emerged as a realistic prospect for the treatment of cancer due to its potential for selective 
tumour cell targeting.  The greatest challenge that cancer gene delivery vectors still face is the 
ability to safely and efficiently deliver genes in order to enable sufficient gene expression into 
target cells. A wide variety of biological and non-biological gene delivery vectors have been 
developed and explored over the past decade. However, gene delivery strategies used to date 
have significant delivery limitations which has slowed the progress of gene therapy to the 
clinical stage.  
 The overall objectives of this thesis are to evaluate the efficacy of various gene delivery 
methods in a clinically relevant tumour model and to also investigate  potential strategies for 
tumour selective delivery. We began with the development of a tumour slice model system 
using patient waste tissue. This model involves the use of fresh human tumour tissue, cut into 
thin slices and maintained ex vivo. The viability of patient tissue samples were only 
moderately reduced under the chosen culture conditions and did not affect the proliferation 
capacity of the cells within the tissues as characterised by the expression of the proliferation 
marker Ki-67. This model potentially represents a more clinically relevant model as it allows 
strategies to be tested on intact patient tissue. Furthermore, a thicker slice, which maintains 
all cellular components and diffusion gradients, would more closely represent the true intra-
tumoural conditions of solid tumours. Through optimisation of tumour slice thickness and 
culture conditions we developed an ex vivo system with the capability of examining both 
biological and non-biological gene delivery systems with real-time analysis of gene delivery. 
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The universal application is achieved by utilising a slice thickness that does not limit nutrient 
and oxygen diffusion throughout the slice while allowing the application of both biological 
and non-biological methods. For real-time measurements of gene expression, we applied a 
bioluminescence imaging technique based on the expression of luciferase. Bioluminescent 
imaging provides a rapid, economical and simple method for monitoring gene expression. 
This non-toxic detection system also enables the sequential quantification of gene expression 
without sacrifice of tissue, allowing for measurement of duration of expression and thereby 
enabling assessment of vectors requiring longer incubation periods. Using this model system 
we evaluated the efficacy of various gene delivery methods in a variety of tissue and tumour 
types. Ad was found to be the most efficient gene delivery vector in breast, colorectal and 
metastatic tumours (Chapter 2 and 3). Among the non-biological techniques, US yielded the 
highest transfection in all tissues. The nature of the ex vivo system also permitted the 
examination of specific physical factors individually, that can account for in vivo reduction in 
gene delivery. Parameters shown to diminish Ad gene delivery included patient blood, 
hypoxia and metastatic disease.  
 The ex vivo model was also suitable for examination of tissue specific effects on 
vector expression. Transcriptional targeting involves regulating the expression of the gene of 
interest by utilising tumour promoters, that maintain a ‘tumour-on’ and a 'normal tissue-off’ 
status. Ad expression mediated by the tumour specific promoter CXCR4 was shown to 
provide a tumour selective advantage over the ubiquitously active CMV promoter in breast, 
colorectal and metastatic liver tumours (Chapter 2 and 3). For the investigation of vector 
efficacy, toxicity and target cell specificity we optimised a dissociation technique, which 
provided representative cells from the entire slice for the accurate assessment of viability and 
identification of targeted cell types. Patient tumour cell population analysis demonstrated that 
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Ad mediated by CXCR targeted a higher percentage of tumour cells when compared with 
CMV. 
 Hypoxia is an important feature of solid tumours as a consequence of a structurally 
and functionally disturbed microcirculation. Hypoxia has been related to the up-regulation of 
gene products that has been shown to promote tumour progression, by enabling tumour cells 
to adapt to nutritional deprivation or to escape a hostile environment. Hypoxia also provides 
an environment directly facilitating chemo- and radio-resistance and also encouraging the 
evolution of phenotypic changes inducing permanent resistance to treatment. A therapy that 
maintains therapeutic profile in hypoxic zones within tumours would improve the therapeutic 
to toxicity index and treatment outcomes respectively. A system of changing oxygenation 
was developed using the hypoxia inducer, cobalt, to mimic the transient hypoxic conditions 
found in solid tumours. Ad-related transgene expression varied depending on the level of 
hypoxia, with significantly reduced levels observed with prolonged hypoxia. However, 
transgene expression was robust in the cycling hypoxic conditions relevant to solid tumours. 
This suggests that Ad may offer a better strategy against the hypoxic component of tumours. 
It is also known that some gene promoters including, CXCR4 are upregulated in hypoxic 
conditions. The CXCR4 promoter was shown to mediate higher gene expression over CMV 
under anoxia while the reversing of chronic hypoxia to normoxic conditions demonstrated 
increased gene expression of both promoters. Therefore, a strategy to re-oxygenate 
chronically hypoxic regions in solid tumours may make them more susceptible to Ad gene 
therapies.   
 A systemically delivered therapy would allow biodistribution of therapeutic to 
metastatic disease in distant organs. The concept of developing a systemically delivered 
vector that localises gene expression to tumour sites is important for the advancement of 
cancer gene therapies. We developed an AAV-based tumour targeting vector using the 
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tumour-selective promoter CXCR4. Comparison of the expression kinetics of CMV with 
CXCR4 following local delivery in murine tumour models revealed that AAV mediated by 
the CXCR4 promoter retained high expression in tumours while maintaining low expression 
in normal tissue (Chapter 4). The systemic delivery of AAVCXCR4 in a hepatic tumour 
model demonstrated enhanced gene expression in tumour-bearing livers with minimal 
expression in tumour-free livers. Furthermore, AAVCXCR4 retained the tumour-selective 
nature in ex vivo patient tumour tissues, confirming the translational potential of this vector. 
  
5.2 Future direction  
We performed gene delivery studies using various vectors in an ex vivo human tumour model 
as we felt this would provide a reliable model for direct extrapolation to the clinical setting. 
The extended duration of culture period and 3D architecture of the ex vivo patient tissue 
model make it universally applicable to studies of novel gene delivery and therapeutic 
strategies where the interplay between tumour cells and the microenvironment are important. 
In addition, the ex vivo tissue culture may also offer a new opportunity to improve the manner 
in which pharmaceutical companies identify potential candidates and bring new therapeutics 
to the market. Currently, immortalized cell lines and stem cells are being used for this 
purpose. While these systems have their advantages, these model fail to accurately represent 
a fully differentiated and functional tissue state. This work has demonstrated that the ex vivo 
model is both reproducible and predictable in a variety of tissue types, which as a result, 
would allow its use from high-throughput screening to safety and toxicology testing. 
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 However, we also recognise that there are important limitations regarding the ex vivo model 
utilised here. Certain tissue types including breast and omental tissue were difficult to culture 
intact due to their lipomatous composition. This resulted in the use of alternative tissues as 
controls.  In addition, the immune system and systemic barriers are underrepresented in the ex 
vivo tumour models. An immune competent model will provide a better understanding of 
additional barriers that vectors must overcome for successful clinical application. We have 
demonstrated that transgene expression can be regulated by transcriptional restriction using 
targeted tumour specific promoters. We have categorically established tumour specific 
targeting using the tumour specific promoter CXCR4. Future work would involve 
incorporating into these vectors therapeutic genes that target either the tumour cells, tumour 
neovasculature or tumour associated cells. An increasing number of studies have reported 
successful tumour targeting using other tumour specific promoters including survivin and 
cyclooxygenase-2 (257, 258). Future comparison and analysis between various tumour 
specific promoters in preclinical models will be invaluable in designing future cancer specific 
vectors. In addition, transcriptional targeting may potentially be extended to other settings 
including non-malignant conditions, such as autoimmune, traumatic or inflammatory 
conditions (199). Furthermore, AdCXCR4 vector demonstrates effective targeting in cobalt 
induced hypoxic conditions.  Cobalt was used to mimic hypoxia due to the luciferase 
bioluminescent detection system requiring molecular oxygen for the production of light. 
Future work would involve the incorporation of a second reporter on each construct, such as a  
fluorescent protein, which would eliminate oxygen dependence, and permit gene delivery evaluation 
using an alternative detection system. Gene delivery to distant tumours for therapeutic 
approaches is a demanding task that urges the development of delivery vectors capable of 
overcoming many obstacles in the systemic circulation. We have demonstrated systemic 
hepatic tumour targeting using an AAV transcriptional targeting vector. Despite the potential 
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shown using transcriptional targeting systems, it is clear that further work is required to 
optimise delivery and to limit potential adverse side-effects. Enhanced gene delivery may be 
achieved by incorporating a strategy of organ selective gene delivery based on both vector 
and disease characteristics. In addition combining gene delivery strategies to achieve 
synergistic effects as previously reported may also be investigated. Further research into 
vector design and targeting will need to proceed in parallel with clinical studies, where proof 
of concept and identification of barriers to clinical gene delivery can inform the next phase of 
clinical research.  
 At the present time, gene therapy may offer the best path for a lifetime unencumbered 
by invasive surgery or toxic conventional therapeutics for the treatment of cancer. With 
continuing efforts alongside the significant progress already made, it is foreseeable in the 
near future that the challenge for the development of a safe, effective and clinically 
applicable gene delivery method for cancer therapy may be finally realised.  
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"There are only two ways to live your life.  
One is as though nothing is a miracle.  
The other is as though everything is a miracle." 
 
Albert Einstein 
 
